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BRIDGING IN VITRO DISSOLUTION TESTS TO IN VIVO DISSOLUTION 




Co-chairs: Gordon L. Amidon and Steven P. Schwendeman 
 
 
Developing meaningful in vitro dissolution methods is critical for evaluating the drug 
in vivo performance and providing a better standard for biowaiver tests. For 
Biopharmaceutical Classification System (BCS) Class II poorly soluble drugs, the 
dissolution tests are especially important because in vivo dissolution is the 
rate-limiting process in oral absorption of drugs. There are many factors affecting the 
in vivo dissolution processes that may have not been fully considered when designing 
the in vitro dissolution tests.  
In this dissertation, in order to bridge the gaps between the in vitro dissolution tests 
with the in vivo dissolution, the human intestinal fluid (HIF) was characterized in 
terms of buffering species and buffer effect on dissolution of acidic drugs using a 
miniature rotating disk dissolution apparatus; Mathematical models such as film and 
reaction plane models were utilized and refined to study the dissolution media factors 
 xii
such as pH, buffering species, and buffer strength on the dissolution of poorly soluble 
acidic drug with known physicochemical properties; Other factors such as CO2 partial 
pressure, the effect of enzymatic reaction in the case of bicarbonate buffer were also 
investigated and discussed.  
The bicarbonate buffer contributes up to 74% to the buffer capacity in human 
intestinal fluid and dissolution of the model drug, ibuprofen, in HIF decreased by 48% 
when HCO3-/CO2 was depleted from ex vivo human intestinal fluid. The two 
mathematical models were in reasonable good agreement of the buffer effect on 
dissolution of ibuprofen. Physiological bicarbonate buffer has been compared with 
United States Pharmacopeia (USP) acetate buffer. With physiochemical properties of 
the drug known, and dissolution buffer can be equated to USP buffer species of proper 
buffer strength to reflect the in vivo dissolution. Other factors, especially partial 
pressure of CO2 and enzyme like carbonic anhydrase have also been shown to affect 
the dissolution through their effect on bicarbonate buffer system. The results provide 
important information and a valuable approach for developing in vitro dissolution test 
for poorly soluble acidic drugs for better in vitro- in vivo correlation (IVIVC) and 
scientific basis for setting biowaiver test standards. 
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CHAPTER I. DESIGNING THE IN VITRO DISSOLUTION TESTS 
EVALUATING THE DRUG PERFORMANCE IN VIVO:    
 FACTORS TO BE CONSIDERED. 
The application of in vitro dissolution tests 
Dissolution tests have been widely used in pharmaceutical industry to characterize the 
release of drug from dosage forms. It is needed in many stages in drug development 
life cycle.  
 
Quality Control: Dissolution was introduced more than 30 years as the quality control 
tools to assure product uniformity and detect batch-to-batch differences of drug 
products occurring during the manufacture processes(1). It also provides the 
possibility to test large number of batches, which is otherwise impossible to test 
clinically. It continues to play an important role in stability tests such as finding out 
the possible product changes during manufacture and storage period affected by 
temperature and humidity. (2) 
 
Bioequivalence and Biowaiver: Dissolution tests are simple, reliable, highly 
reproducible methods that allow monitoring the product quality efficiently and could 
be used to establish the equivalence between formulations at different stage of 
development and also different sites or scale for manufacturing. By using carefully 
designed dissolution tests , which considered the multidimensional combinations and 
interactions of both the drug and material attributes and process parameters, the 
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quality could be assured from the early stage of development.(3) 
 
Formulations development and in vitro- in vivo correlation (IVIVC): In recent years, 
dissolution tests have received increasing attention for its function of serving the 
surrogate for in vivo availability. The relationships between in vitro dissolution and in 
vivo input rate have been categorized into four different levels, A, B, C and multiple 
level C correlations. A level A correlation represents a point-to-point relationship 
between in vitro dissolution and the in vivo input rate, which is the considered the 
most informative and also very useful from a regulatory viewpoint. Generally, these 
correlations are linear; however non-linear correlations are also acceptable. A level B 
IVIVC uses the principles of statistical moment analysis, correlating the mean in vitro 
dissolution time to either the mean residence time or the mean in vivo dissolution time. 
The level B uses the information from the whole in vitro and in vivo data, but it is not 
uniquely reflect the actual in vivo plasma level curve. A level C correlation establishes 
a single point relationship between a dissolution parameter (e.g. T50% or percent 
dissolved in 4 h) and a pharmacokinetic parameter (e.g. AUC or Cmax). A multiple 
level C correlation relates one or several pharmacokinetic parameters of interest to the 
amount of drug dissolved at several time points of the dissolution profile (4-6). For 
novel drug delivery systems and modified release products, the establishment of 
IVIVC helps in establishing dissolution specifications and allows the waiver for in 
vivo bioequivalence study (7-12). For novel drug products, the dissolution is the 
essential screening tool to select the formulation for clinical trials. The dissolution 
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tests help to reduce the cost, assess product performance more directly and avoid the 
complex and variable pharmacokinetic profiles which are caused by the complications 
such as post-absorption, enteroheptic recycling and highly variable drugs, which are 
defined as drugs with within-subject variability (WSV) of the maximum concentration 
(Cmax) equals or exceeds 30%  (13, 14),. It also offers benefits in terms of ethical 
consideration and speeds up the development decision making process.(15)   
 
Biopharmaceutical classification system and BCS II drugs 
Biopharmaceutical classification has provided the scientific basis for the correlation 
of in vitro drug product dissolution and in vivo bioavailability and has been adopted 
by FDA as the guidance for the waiver of in vivo bioavailability and bioequivalence 
studies for immediate release solid oral dosage forms (16, 17). Based on the model 
analysis on dissolution and absorption(18), drugs are classified into four high/low 
solubility-permeability classes with the expectations of their in vitro-in vivo 
correlations more clearly stated in Table 1.1.  
(Table 1.1) 
 

























0 =⋅ ρ  is low. Here, the effP  is the effective permeability of the 
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drug, Cs is solubility of the drug, R is the intestine, tres and tDiss is the mean residence 
time and the time required for a particle of drug to dissolve. ro is the initial particle 
radius. The dissolution in vivo is then the rate limiting step in drug absorption except 





= ).Dissolution profile will determine the 
concentration profile along the intestine for a much great period of time when 
intestinal luminal contents, intestinal membrane change along the intestine and much 
more of the intestinal content is exposed to the intestine. Figure 1.1 shows the for high 
permeability drugs, the estimated fraction dose absorbed depends on the dose number 
D0,and dissolution number Dn. This work stated the possibility of the IVIVC for Class 
II drugs. Correspondingly, the in vitro dissolution profile should also be determined at 




Since most new chemical entities developed as drug candidates are poorly soluble 
compounds (19, 20). Therefore, a lot of efforts are being made to overcome the 
difficulties of low solubility for developing new drugs as oral dosage forms. In which, 
the IVIVC is useful in helping to select and make desired formulations, but it is not 
easy to achieve especially when dissolution methods are not developed to reflect the 
in vivo dissolution kinetics.  
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Physiological factors contributing to the in vivo dissolution  
The in vivo dissolution rate is not only affected by the physiochemical properties of 
the drug, but also the gastrointestinal (GI) physiological factors: the pH, the 
composition and hydrodynamics of the GI fluid caused from the motility of GI, the 
secretions of the glands and mucosa, food and drug intake, etc. All these factors 
interact with and result from each other and also with the drug properties determining 
the final level of drug dissolution and further absorption of the drug into the systemic 
circulation and amount available at the sites of actions.  
 
Gastrointestinal pH 
The pH gradients existing all along the gastrointestinal tract has been studies from 
early in 1960s using the telemetering capsule or electrode and later multichannel and 
online measurements (21-25). It is affected and in reserve affected by gastric 
emptying, the secretion of the glands and mucosa, bactericidal effects(26) and disease 
states or treatment (27-32), enzymes and transporters along GI(29) and also drug 
administration and food feed (33, 34). In health subjects, the intraluminal pH is 
rapidly changed from highly acidic of 1-3 in the stomach (fasted pH1.3 (1.1-1.6) 
versus fed state 4.9(3.9-5.5) to about pH 5-7 in the duodenum (fasted duodenal pH, 
6.5 (6.2-6.7); and duodenal pH during the meal, 6.5 (6.4-6.7)), then gradually 
increases in the small intestine from pH 6 to about pH 7.4 in the terminal ileum. 
Finally, pH drops to 5.7 in the caecum, but again gradually increases, reaching pH 6.7 
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in the rectum.(29,35,36). The pH gradients from studies along normal human subjects 
are list in Table 1.2.  
(Table 1.2) 
For acidic solubility limited drugs, studies have shown that drug dissolutions in buffer 
solutions are much higher than their intrinsic dissolution rates (37, 38). The results 
suggest that the poorly water soluble BCS Class II weak acid NSAIDs would have 
higher solubility because of highly ionized in intestinal environment, thus the 
dissolution process will also be faster.  
 
Gastrointestinal motility 
The gastrointestinal responses to food and drug intake are characterized by two 
patterns, inter-digestive pattern and the digestive motility pattern, with different upper 
GI motility and secretions which are regulated by the nervous system and the 
hormones (39-43). The inter-digestive pattern or the recurring cycles of intense 
contractile activity is termed as the migrating motor complex (MMC)(44) and been 
divided into four different phases. Phase I is a quiescent period. Phase II is a period 
with intermittent and irregular contractions with increasing strength, its contractile 
activity accumulates in a short period. Phase III is called the gastrointestinal 
interdigestive housekeeper and its contractile activity usually initiates from antrum 
and duodenum, also proximal jejunum(45), then migrates along the small intestine 
distally. It is also known as the interdigestive migrating myoelectric complex (IMMC). 
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The human MMC activity varies widely between individuals and within the same 
individual on separate days(46). The IMMC cycle is typically 90-120 minutes but 
could vary from 15min to 3 hours.(45, 47, 48) The pH of the duodenum is also 
believed to affect the IMMC in humans. Phase IV are sometime referred as the short 
period transition from phase III to Phase I.(49) 
 
The motility plays an important role in the gastrointestinal environment interacting 
with different factors such as gastric emptying, luminal fluid volume, flow rates(47), 
pH(50), luminal metabolism, blood flow and their interactions with the drugs will also 
affect the drug in vivo dissolution and absorption. The transit time could also affected 
by gastrointestinal symptoms and also drug treatment (30, 51, 52)  
Composition of gastrointestinal fluids 
Gastrointestinal fluids are the media that oral drugs directly encounter after 
administration. Its composition therefore is very important for study the in vivo 
dissolution process. Besides the exogenous liquids, foods, drugs and their metabolites 
such as lecithin, monooleins, long chain fatty acids and/or triglycerides(53), the GI 
fluids are constituted of physiological buffers, bile salts, enzymes.  
 
Bicarbonate is secreted from pancreas, gall bladder and duodenum mucosa into the 
duodenal chyme as the primary protection from the gastric acid (54, 55). Pancreatic 
fluid has a bicarbonate concentration of between the basal 25 mmol/l and 150 mmol/l 
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postprandial and up to 200 mmol in a 24 hour period. The bile from the gallbladder 
has a bicarbonate concentration of about 40 mmol/l. The duodenal mucosa also 
generates and secretes bicarbonate. Jejunum secrets small amount of proton and ileum 
secretes bicarbonate, and ileum could secret bicarbonate over 200 mmol per day into 
intestinal lumen. Most of the bicarbonate is consumed by organic anions from the 
acids which are the metabolites by bacteria.(56)  
 
The intubation studies early in 1935 already showed that bicarbonate concentration 
ranged from 4.0-21.1 mM, jejunum 5.8 mM, upper ileum 2.3mM, middle ileum 3.9 to 
39.8mM lower ileum 10.4-17.0mM(57). McNamara reviewed the bicarbonate luminal 
concentrations listed in Table 1.3(58).  
(Table 1.3) 
More recent research reported the buffer capacities of human jejunumal fluids are 
2.4-2.8 mmol L-1 pH unit -1 in fasted state with pH 7.5 and 13.2-14.6 mmol L-1 pH 
unit -1 with pH 6.1 in fed state, the corresponding bicarbonate buffer concentration 
calculated as 16.5-19.3mM for fasted and 25.4-27.7 mM for fed state, and 5.6 mmol 
L-1 pH unit -1for fasted duodenum converted to bicarbonate of 10mM at pH6.2 (59, 
60) 
 
The ionic composition of the dissolution buffer could greatly affect the dissolution of 
ionizable drugs and is critical for solubility limited ionizable drugs even at the same 
pH (61-64). Currently, most of the dissolution buffers in applications are with 
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non-physiological buffer species and may not reflect the real in vivo dissolution 
profiles of BCSII drugs. So it is important to decide the methods including the buffers 
that should be used in the in vitro dissolution test to predict more accurately the in 
vivo dissolution. 
 
Dissolutions of drug in products  
Since drugs are always given in certain dosage forms, the formulation factors, the 
manufacture procedures and the physiochemical properties of the drugs will all 
influence the in vivo dissolution. The formulation factors includes the granule size, the 
particle size distribution, homogeneity and polymorphisms of the materials, and 
drug-excipient interactions; Attention should also be paid to the factors in 
manufacture process such as compression force, temperature, moisture and storage of 
the dosage forms; The physiochemical properties of drug itself, such as solubility, pka, 
diffusion coefficient, partition coefficient, chemical stability and dose are also 
essential. All of these factors interact with the physiological factors, thus as a result, 




Bridging the in vitro tests to in vivo dissolution process and dissolution 
media consideration 
Investigating the in vivo physiological and pathological situations 
To bridge the discrepancy between the in vivo dissolution tests to the in vivo 
dissolution process, it is critical to investigate the in vivo physiological and 
pathological situations. The more pieces of information could allow us to have a more 
complete and clear picture of what the key factors are limiting the dissolution.  
Mathematical Models describing the dissolution tests 
Mathematical models have been developed to provide a better way to understand the 
drug dissolution process or the release from the formulations quantitatively and. 
qualitatively. In 1897, Noyes and Whitney published that the solid substance 
dissolution rate would be affected by their own solution concentration(65). The 




where dM/dt is the dissolution rate, dM is the amount of drug dissolved in unit time t, 
Cs is the solubility of the drug, Ci is the concentration of the dissolved drug, k is 
dissolution rate constant. 
 
Nernst and Brunner modified the original Noyes-Whitney equation, consider the 









where dM/dt is the dissolution rate, dM is the amount of drug dissolved in unit time t, 
D is the diffusion coefficient, V is the volume of dissolution media, S is the surface 
area, h is the thickness of diffusion layer, Cs is the solubility of the drug, Ci is the 
concentration of the dissolved drug(66, 67).  
 
The empirical model, Weibull model based on the distribution were proposed and 
applied to dissolution curves successfully(68, 69).  
M = 1-exp(-αtβ), 
where M is the fraction of accumulated drug in solution at time t, α, β is a scale factor 
and shape factor respectively. For sparingly soluble, suspended drugs, diffusion 
transport plays an important role in the dissolution kinetics and the apparent diffusion 
distance(70) is 
hAPP=DCS/G 
where D is the diffusion coefficient, Cs is the equilibrium solubility, and G is the 
surface specific dissolution rate. 
  
Based on the film model of Olander (71, 72), Mooney et al. (64, 73) investigated the 
pH and buffer effect on the solubility and dissolution of ionizable drugs. McNamara 
et al also developed a convection diffusion model, reaction plane model, taking into 
account the irreversible reaction of the dissolved species with buffer in the 
hydrodynamic boundary layer. (62, 74)  
 
 12
Combination of experimental and theoretical approaches reflecting the in vivo 
process   
Although developing the in vitro dissolution methods that could reflect the in vivo 
dissolution process is complicated with all above factors involved. We will first 
consider the dissolution media which plays an important role in the process and get 
started to understand the in vivo dissolution conditions. The contribution of 
bicarbonate buffer in human intestinal fluid to buffer capacity and its effect on the 
dissolution of model drug, ibuprofen (Figure 1.2 lists the structure and properties of 
Ibuprofen) will be investigated. Since physiological bicarbonate buffer is hard to be 
prepared and maintained due to its complicated dissociation and equilibrium with the 
CO2(75), the buffer effect on the dissolution of model compound, ibuprofen will be 
compared in compendia acetate buffer and physiological bicarbonate buffer. The 
comparison will be done both experimentally by the intrinsic dissolution and 
theoretically with film model and reaction plane model. The effect of CO2 partial 
pressure and carbonic anhydrase enzymatic effect on the bicarbonate dissolution 
buffer will also be explored.  
. (Figure 1.2) 
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*A limited correlation means that the dissolution rate while not rate controlling may 
be similar to the absorption rate and the extent of correlation will depend on the 
relative rates. 
Table1.1  In Vitro – in vivo (IVIV) correlation Expectations for Immediate 
Release Products Based on Biopharmaceutical Class (reproduced from (16)) 
 
Class Solubility Permeability IVIV correlation Expectation* 
I High High IVIV correlation if dissolution rate is slower than gastric 
emptying rate, otherwise limited or no correlation  
II Low High IVIV correlation expected if in vitro dissolution rate is 
similar to in vivo dissolution rate, unless dose is very high. 
III High Low Absorption (permeability) is rate determining and limited 
or no IVIV correlation with dissolution rate. 
IV Low Low Limited or no IVIV correlation expected. 
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Figure 1.1 Graph of estimated fraction dose absorbed vs Dissolution Number, Dn, 
and Dose Number, Do, for a high permeability drug. An = 10 corresponds to a 
drug with a permeability approximately that of glucose. 
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Table1.2 Median or mean gastrointestinal pH levels of normal, adult human 
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Maxwell et al, 
1971 (99) 
10 - - 
5.5-
6.5 
- - - - - - - - - 
Bown et al. 
1974 (101) 
11 - - 5.9 6.8 7.5 - - - 6.0 - - 6.8 
Evans et al. 
1986 (102) 
23 - - - - - - - - 6.2 - - 
6.7
5 
Patil et al. 1988 
(103) 







Pye et al, 1987 
(104) 
8 - - - - - - - - 6.5 - - 7.3 
Gilbert et al, 
1988 (35) 
42 - - 6.61 - 7.50 6.37 - - - - - - 
Evans et al. 
1988 (35) 
66 1.75 - 6.63 7.41 7.49 - - - 
6.3
7 
- - 7.0 
Fallingborg et 
al, 1989 (11) 





al, 1989 (45) 
6 - - - - 7.3 - - - - - - - 
Raimundo et al, 
1992 (107) 
7 - 5.8 6.6 - 7.4 - - - 6.7 - - - 
Wyeth et al. 
1992 (107) 




al, 1994 (34) 
13 - 6.22 6.06 - - - - - - - - - 
Press et al, 
1996 (48) 
12 - - 6.7 - 7.4 6.0 - - 6.0 - - 6.2 
Sasaki et al, 
1997 (37) 
4 1.4 - 6.8 - 7.7 - - - 6.8 - - 7.2 
Fallingborg et 
al, 1998 (15) 
13 1.4 - 6.4 7.1 7.4 - - - 5.8 - - - 
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CHAPTER II. DISSOLUTION OF ACIDIC DRUGS: THE ROLE 
OF BICARBONATE IN HUMAN INTESTINAL FLUIDS 
 
Abstract 
Drug dissolution rate can be significantly affected by the buffer species in dissolution 
media. Bicarbonate has been recognized as the predominant buffer system in human 
GI tract for a long time. Therefore, quantitatively determining bicarbonate buffer 
contribution to the buffer capacity in ex vivo human intestinal fluid (HIF), and its 
effect on acidic drug intrinsic dissolution, are important for predicting the in vivo 
dissolution of acidic drugs.  
Human intestinal fluids with HCO3-/CO2 as collected and depleted were titrated from 
pH 7.0 to pH 3.0 to determine the carbonate contribution to the buffer capacity. The 
HCO3-/CO2 species were also determined using ion chromatography (IC). The 
dissolution of the model compound, ibuprofen (weak acid, pKa 4.4), was conducted at 
pH 6 in HIF with HCO3-/CO2 as collected or depleted using a miniaturized intrinsic 
dissolution release apparatus.  
The overall buffer capacity from original HIF varied from 2.9 to 5.8 mM H+/(L HIF* 
pH unit), to which the bicarbonate contribution was 18% at pH 3.0 to 59% at pH 6.5, 
with the highest 74% at pH5.5. The absolute concentration of HCO3-/CO2 buffer 
determined by titration was 4.5 mM, which was consistent with the IC results of 4.3 
mM for bicarbonate and only 0.62 mM for phosphate. Further, at pH 6.0, the 
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bicarbonate contributed of 57% to the total buffer capacity in HIF, and resulted in a 
48% decrease of ibuprofen flux in HIF depleted of HCO3-/CO2 compared with that of 
non HCO3-/CO2 depleted HIF. 
The results of the present work demonstrated that bicarbonate buffer contributed 
significantly to the buffer capacity in HIF, and plays an important role in the 
dissolution of acidic drugs in vivo. Since in most cases, aspirated intestinal fluids may 
be partially depleted of HCO3-/CO2, the impact of bicarbonate on acidic drug 
dissolution is likely underestimated .The information of buffer species and strength 
obtained by characterizing HIF will aid in the design of dissolution media that are 





Understanding the gastrointestinal (GI) physiology is extremely important in 
developing an in vitro dissolution method to help formulation screening or control 
drug product in vivo quality. Many factors have been studied over the past years, such 
as GI fluid pH, volume, composition, transit time, motility, also effect of food, disease 
state, gender and age(76, 77). Buffer species and capacity to be used in the in vitro 
dissolution test have been showed influencing the dissolution rate of ionisable drugs 
(58, 63, 78). 
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For acidic drug taken orally, after experiencing the gastric low pH, the drug is emptied 
in to upper intestinal tract, where the pH is higher and variable. It is in this region of 
the GI tract where the dissolution of drug from formulation plays a critical role in 
determining the bioavailability. Bicarbonate secretion has been recognized as the first 
line defense to protect intestinal mucosa from gastric acid and pepsin. HCO3- is 
secreted by pancreas, liver and epithelial cells to neutralize the gastric hydrochloride 
acid and help to establish the pH gradient in mucus gel (79, 80). Pancreatic fluid has a 
25 mmol/l basal HCO3- concentration and postprandial concentration can reach 150 
mmol/l. The total pancreatic bicarbonate secretion is about 200 mmol in one day. Bile 
from gall bladder has HCO3- concentration about 40 mmol/l. Basal duodenual 
mucosal output of HCO3- is 0.355 mmol/cm-1﹒h-1(81). Overall, in spite of lacking of 
firm data, the net bicarbonate secretion in excess of proton secretion into the gut 
lumen is about 20 to 40 mmol/day(56). HCO3- is also in reversible reaction with CO2 
dissolved in water which is further in equilibrium with CO2 in gas. 
The use of bicarbonate buffers which reflecting the in vivo buffer environment has 
showed obvious advantage over non physiological buffer species. There are attempts 
made to using bicarbonate buffers system to discriminate different formulations (82, 
83), also different methods are discussed to maintain the stable bicarbonate 
systems(78) . The efforts have also been made to develop compendial buffer system in 
which drugs has the equivalent flux as in bicarbonate (63) . It is still important to find 
out the bicarbonate strength of in human intestinal fluid and its effect on drug 
dissolution directly.  
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In this study, we used a special designed differential titration method and determined 
the bicarbonate buffer capacity in fasted human intestinal fluid (HIF) directly. The 
results are compared with those from ion-exchange column experiments on the same 
HIF. The dissolution of the model compound, ibuprofen (weak acid, pKa 4.4), was 
conducted at pH 6 in HIF with HCO3-/CO2 as collected or depleted using a 
miniaturized intrinsic dissolution release apparatus. 
The objective is to determine the contribution of bicarbonate in buffer capacity of HIF 
and its effect on drug dissolution. 
 
Material and methods: 
Collection of Human Intestinal Fluid 
Human small intestinal fluid was collected using Loc-I-Gut technique from proximal 
jejunum (84, 85). Subjects are fasted 10 hours before collection, samples are pooled 
from 11 men and 6 women aged from 23 to 43. pH of fluid was measured right after 
collection to be 7.1(n=2, 7.0 and 7.1). Samples of fluid are frozen quickly to be used. 
 
Determine bicarbonate capacity in Human Intestinal Fluid by differential 
titration 
For determining the bicarbonate capacity in HIF, a differential titration method is 
designed to determine the whole buffer capacity of HIF as collected and that of the 
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HIF depleted HCO3-/CO2, therefore, the difference of those two buffer capacities is 
the portion contributed by HCO3-/CO2 in HIF. 
 
Measure the whole HIF buffer capacity 
1 mL HIF was transferred into a scintillation bottle, and then covered with a layer of 
paraffin oil to prevent the further CO2 dissolving and CO2 evaporation. The bottle was 
placed in 37C water bath with circulating water. pH was recorded with a pH 
meter( fisher scientific accument AB15). HIF was titrated with 1mol/l HCl using a 
microsyringe while the mini magnetic bar stirring at the bottom, pH was recorded till 
it reached down to pH 3 when adding every 2 µL of HCl.  
 
Measure the whole HIF depleted of HCO3-/CO2 buffer capacity 
 
1 mL HIF was transferred into a scintillation bottle and kept in 37C water bath and pH 
of HIF was recorded. 1 mol/l HCl was used to adjust pH to 6.1, which is the pKa of 
carbonic acid at 37C. Moistened nitrogen gas was purged through the samples under 
maximal stirring for 1 hr and pH is recorded again. If pH increases due to CO2 loss, 
adjusted it to pH6.1 using 1 mol/l HCl and repeated the step of purging the sample 
with nitrogen, till the pH of the sample is stable in the range of 0.1 pH unit for at least 
1 hr. Recorded the final pH. Bottles are weighed before and after these step to make 
sure no significant moisture lost. Covered HIF with paraffin oil and adjust pH to 
original pH with 1mol/l NaOH. The bottle was again kept in 37C water bath, 1mol/l 
HCl was used to titrate the fluid with the same method as titrated the whole HIF 
buffer capacity till pH below 3. 
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Anion Exchange chromatography determining the carbonate and phosphate 
strength in HIF 
The total carbonate strength and phosphate strength in HIF were also investigated 
using ion exchange chromatography (IC) equipped with ASRS 4 mm suppressor and a 
Dionex IonPac AS11 column (4 x 250 mm) ( Dionex, Sunnyvale, CA). 100 µL HIF 
was mixed well with 100 µL acetonitrile, centrifuged with 10,000 x g for 15 min at 37 
C, and the supernatant was diluted 20 times and analyzed via IC. The mobile phase 
was isocratic 5mM KOH, Suppressor current was 13mA, and flow rate was 1mL/min. 
Standards were prepared using Na2HCO3 from 0.05mM to 1mM and Na2HPO4 0 to 
0.1mM. 
 
Intrinsic Dissolution in Human intestinal Fluid 
Mini-scale intrinsic dissolution apparatus 
A mini-scale intrinsic rotating disk dissolution apparatus was designed for using small 
volume HIF. The drug tablet was also scaled down from the traditional and a load cell 
(0-500lbs) (transducer techniques, Temucula, CA) was attached to carver compressor 
to monitor the pressure applied when making mini-tablets. The apparatus was 
validated by comparing the results from the intrinsic dissolutions in the conventional 
rotating disk apparatus with in the new mini-scale apparatus using model compound, 
benzoic acid in 0.1M HCl dissolution media. 
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Dissolution of Model compound Ibuprofen in HIF 
Dissolution tests were conducted with mini-scale rotating disk dissolution apparatus. 
HIF was used as dissolution media, 5mL HIF purged with CO2 and reached 
pH6.0.The same experiments were also conducted in 5 mL HIF depleted of 
HCO3-/CO2 by using the moistened nitrogen with the same method as described 
earlier and adjusted pH to 6.0 before starting the experiments. The temperatures of the 
fluid were kept at 37C and the disk rotating speeds were 100rpm. 10 µL samples were 
taken at 1, 3, 5,10,15,20 min. The samples were mixed with equal volume of 
acetonitrile, centrifuged with 10,000 x g for 15 min at 37 C, and the supernatant was 
analyzed using high performance liquid chromatography (HPLC). Standards were 
prepared with HIF spiked with Ibuprofen from 0.66µg/mL to 3.32µg/mL. Each 
experiment is done in duplicates. 
 
Recovery experiment and Assay 
Blank HIF was spiked with ibuprofen of 2,3,5,8,10 µL of 33.16 µg/mL ibuprofen 
solution in mobile phase. A standard of 100% recovery was prepared by diluting 
33.16 µg/mL ibuprofen solution in mobile phase respectively. The recovery 
percentage was calculated by ratios of areas of the peaks obtained from HIF samples 
with the areas obtained from the recovery standards. 
 
Dissolution of Ibuprofen in bicarbonate buffer in different concentrations at pH 
6.0 
 24
Dissolution studies of Ibuprofen were also tried in traditional IDR setting with 
different concentrations of bicarbonate buffers at 37C purged with CO2 and maintain 
the pH 6.0 by adjusting the flow of CO2. The experimental conditions were the same 
with the experiments with HIF. Each experiment was done in triplicates. 
 
Results 
Bicarbonate capacity in Human Intestinal Fluid 
Determining HIF buffer capacity:  
The representative titration curves are showed on Figure 2.1. 
(Figure 2.1) 
The curves illustrated the pH changes of ex vivo HIFs with original CO2/HCO3- and 
with CO2/HCO3- depleted during the titrations. Each type of titration was run in 
duplicates and the results were consistent between different runs. The slope of the 
curve shows the pH change due to the added acid. At where the slope is steep, the 
fluid has smaller buffer capacity, because, for certain unit pH change, only smaller 
amount of acid is needed. The buffer capacities of both were calculated according to  
d(pH)
dn  capacity)(buffer   =β  
where dn is the amount of added acid and d(pH) is the resulting change in pH. 
In each experiment, the slopes of the lines in 0.5 pH intervals between 7.0 and 3.0 
were calculated. The results are showed in Figure 2.2. 
(Figure 2.2) 
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The buffer capacity ranged from 0.95 to 4.73 mM H+/(L HIF * pH unit) for HIF 
depleted of CO2/HCO3- and from 2.80 to 5.77 H+/(L HIF * pH unit) for ex vivo HIF 
with CO2/HCO3- for pH 5.5 to pH 3.0.The later was consistent with fasted state ex 
vivo HIF capacity reported by Persson et al and Perez de la Cruz Moreno et al (59, 86). 
With the CO2/HCO3- being depleted, the buffer capacities of HIF are significantly 
reduced in the whole pH range, the difference was contributed by HCO3-/CO2.  
 
The contribution of HCO3-/CO2 in whole ex vivo HIF was also determined by the ratio 
of this difference in buffer capacity of these two HIFs to the whole HIF. The results 
are showed in Figure 2. 3. 
(Figure 2.3) 
The contribution of bicarbonate to the overall buffer capacity in the ex vivo HIF was 
pH dependent, ranging from 18% at pH 3.0 to 59% at pH 6.5 with the highest 74% at 
pH 5.5. When pH was higher than 5, the contribution of bicarbonate was mostly larger 
than 50%, confirming bicarbonate is dominant in fasted state ex vivo human intestinal 
fluid. 
 








Where the C is the total buffer concentration, Ka is the dissociation constant; [H+] is 







HKaC β  
Where, β had been determined from the experimental results.  
The bicarbonate buffer concentration was calculated to be 4.5mM at pH6.0, since 
carbonate pka is 10.3 which is 4 unit above pH6.0, CO32- should be negligible 
comparing to HCO3-.  
 
Anion Exchange chromatography determining the carbonate and phosphate 
strength in HIF: 
The concentration bicarbonate determined by Anion exchange chromatography was 
4.30± 0.43 mM (n=2), which was pretty close to the bicarbonate concentration 
determined by the differential titration. The phosphate ion in HIF was only 0.62mM 
although phosphate is used as compendial buffer species.  
 
Intrinsic Dissolution in Human intestinal Fluid 
Mini-scale intrinsic dissolution apparatus 
A miniature rotating disk apparatus was designed to scale down the drug and fluid 
samples needed from the traditional apparatus. The blueprint of the disk and module 
is showed in Figure 2.4.The mini tablets were made by carver laboratory presser 
(Summit, NJ) attached with a transducer loading cell (transducer techniques, 
Temucula, CA) measuring the pressure on the tablet. The mini-scale intrinsic 
dissolution apparatus was successfully validated using benzoic acid as testing 
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compound. The comparison of the key parameters of the miniature rotating disk 
apparatus to the traditional one was listed in Table 2.1. Much less active 
pharmaceutical ingredient (API) and dissolution media are needed as compared, 
which served the purpose of using HIF as the dissolution media. 
(Figure 2.4) 
(Table 2.1) 
Table 2.2 shows the flux escaped from the solid surface when benzoic acid was used 
as a testing compound in both traditional and miniature dissolution apparatus. The 
ratio of these two flux values is 0.9973, which indicated that the new dissolution 
apparatus was suitable for dissolution study with HIF. 
(Table 2.2) 
 
Dissolution of Model compound Ibuprofen in HIF 
The pH changes during the dissolution experiments were monitored to be less than 0.1 
unit in HIF depleted CO2/ HCO3-.The pH value remained almost constant for 
experiments in the whole HIF with CO2/ HCO3- as collected. The IDR dissolution 
profiles were obtained and the drug fluxes from the surface of the drug disk were 
calculated and listed in Table 2.3. Recovery of the ibuprofen from HIF ranged 92% to 




Dissolution of Ibuprofen in bicarbonate buffer in different concentrations at pH 
6.0 
When purging CO2 to 30mM and 25mM sodium bicarbonate buffer at 37C in open 
container, after 1 hour, the pH could only reach to 6.18 and 6.09. So the dissolution 
studies of Ibuprofen were performed with 10mM and 20mM sodium bicarbonate 




The bicarbonate impact on the buffer capacity and dissolution of weak acid drug 
Our studies showed that the bicarbonate was contributing more than 50% to the buffer 
capacity of fasted ex vivo intestinal fluid in pH 5.0 to 7.0 range. At pH 6.0, the 
bicarbonate contributed to 57% of the total buffer capacity in HIF, which resulted in 
an about 50% decrease of ibuprofen flux in HIF depleted of HCO3-/CO2 compared 
with that of non HCO3-/CO2 depleted HIF. These showed that the bicarbonate 
contributed significantly to the dissolution of weak acid drug in vivo even with 
relatively low concentration. The 20mM bicarbonate buffer with total HCO3-/CO2 of 
45.18mM had about the equivalent intrinsic dissolution rate to the non-bicarbonate 
portion of HIF at pH6.0. These results suggested that the effect of bicarbonate buffer 
strength on acidic drug dissolution rate was not simply linear additive.  
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Partial pressure effect on the HCO3-/CO2 in HIF 
The HCO3-/CO2 concentration in ex vivo human intestinal fluid was only 4.3 or 4.5 
mM. However, in HCO3-/CO2 system, the partial pressure of CO2 will affect the 
HCO3- in buffers. At normal atmosphere, partial pressure of CO2 (PCO2) is 3.5 x 10-4 
atm. The concentration of HCO3-, H2CO3 and total concentrations were calculated in 
Table 2.5. (88) 
(Table 2.5) 
So the HCO3-/CO2 concentration in ex vivo human intestinal fluid is 100 times higher 
than that resulting just from dissolving CO2 under normal atmosphere. While PCO2 in 
normal atmosphere is only 0.03% atm, the resting PCO2 in lumen is 38mmHg (5% 
atm), which is comparable to PCO2 in arterial blood. Postprandial PCO2 could increase 
to 280mmHg (37%atm) or even higher (58, 89, 90). Table 2.6 calculated the HCO3- at 
these conditions. 
(Table 2.6) 
The  [HCO3-]  calculated are in the same range with the experimental measured  
[HCO3-] (58). Since in most cases, aspirated intestinal fluids may be already partially 
depleted of HCO3- during the collection, storage and handling, the impact of 
bicarbonate on acidic drug dissolution is likely to be underestimated here. 
 
Interplay of different factors on HCO3- strength 
Bicarbonate is unique in physiological buffers because the system is open- ended and 
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the continuous removal of acids is made possible by inhalation of CO2. It is the most 
powerful extracellular buffer in the body, and buffers up to 90% hydrogen ions in 
extracellular fluid(91). The lumen HCO3- concentration is in equilibrium with H+, 
H2CO3, CO2 (aq) and CO2 (gas) with the facilitation of carbonic anhydrase as showed 
in Figure 2.5.The HCO3- secretion in collaboration with mucus plays important role in 
mucosal protection through two ways: one is neutralization of luminal acid directly by 
secreted HCO3- in the lumen and mucus gel; the other is the establishment of pH 
gradient in the mucus gel with the aid of the physicochemical property of mucus(79). 
Our studies provided a clearer description of HCO3- in fasted state GI fluid and its 
effect on weak acid drug dissolution. More investigations are needed in determination 
of the actual in vivo HCO3- buffer strength, thus further determining the proper in 
vitro buffer strength for this group of drugs is possible. 
(Figure 2.5) 
 
pH, mucosal secretion, bateria,enzymes,transporters,disease change effects 
Sham-feeding and the presence of acids in upper small intestinal trigger the PCO2 
changes and secret HCO3- mediated by E- prostaglandins and vasoactive intestinal 
peptide(VIP), to maintain the pH and protect the mucosa from the damage of the acids. 
This process is also regulated by transporters (NHE,AE, CFTR) (81, 92-94), 
enzymes(carbonic anhydrase) (95) and neurohumoral process(96) (97-100). The 
secretion of HCO3- is also closely related to the activity of intestinal alkaline 
phosphatase(101), the development of ulcers(102) and also H. pylori infection.(103) 
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Smoking and NSAIDS like indomethacin also inhibit stimulation of HCO3- secretion 
by luminal acid.(104) 
In physiological condition, HCO3- is secreted to response to food and luminal acid. In 
the disease state, the physiological secretion may be disturbed and the normal balance 
or activities will be disrupted when the different factors regulating bicarbonate 
involved. When drugs are taken orally to treat the disease locally or systemically, they 
add another dimension to the complexity of whole the system. It is very hard to 
understand the interactions of all these factors in GI bicarbonate system, but the 
capturing of the characteristics of in vivo gastrointestinal the bicarbonate buffer 
strength at different stages of digestive cycle and its effect on acidic drug dissolution 
will provide a baseline to develop the dissolution methods that could meet the needs 
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Figure 2. 1 Representative titration curves of ex vivo HIF. The diamond dotted 
line shows the original HIF containing CO2/HCO3- titration curves of ex vivo HIF, 
and the triangle dotted line shows the HIF depleted of CO2/HCO3-. 
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Figure 2. 2 Illustrates the buffer capacities of ex vivo HIF with CO2/HCO3- and 
with CO2/HCO3- depleted. The diamond dots show the original HIF containing 
CO2/HCO3-, the triangle dots show the HIF depleted of CO2/HCO3- at different 
pHs. Standard deviations from duplicate runs are showed with the error bar 










































Figure 2. 3 The percentage contribution of bicarbonate to the whole ex vivo 




 Figure 2. 4 The drawing the mini-scale rotating disk apparatus.
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 Traditional Miniature 
Tablet Diameter (cm) 0.90 0.16 
Tablet surface(cm2) 0.64 0.020 
Compression force (lbs) ~2000 ~100 
API needed (mg) 200 5 
Media needed(ml) 200 5 
Table 2.1 Comparison of the key parameters of the miniature rotating disk 
apparatus to the traditional apparatus.  
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  Traditional(n=3) Miniature(n=3) 
Flux from the surface 
(mg/cm2/min) 
0.7418 ±0.0032 0.7393±0.0018 
Table 2.2 Comparison IDR tests of benzoic acid in 0.1M HCl using traditional 
and miniature apparatuses. 
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  Drug flux 
(j(mg/cm2/min) 
Std Dev.(n=2) 
pH6.0 HIF with CO2/ HCO3- 0.1552 0.0012 
pH6.0 HIF with CO2/ HCO3- depleted 0.0805 0.0053 
Table 2.3 The drug flux from the surface of the drug disk in pH 6.0 HIF with and 






of CO2/ HCO3-. (mM) 
Drug flux ±s.d. (mg/(cm2*min)) 
10 22.59 0.06736 ±0.002542 
20 45.18 0.08377 ±0.007569 




pH 5 6 6.8 
[H+](Mol/L) 1.00E-05 1.00E-06 1.58E-07 
[H2CO3](Mol/L) 1.18E-05 1.18E-05 1.18E-05 
[HCO3-](Mol/L) 5.13E-07 5.13E-06 3.24E-05 
Total [H2CO3]+[HCO3-](Mol/L) 1.23E-05 1.69E-05 4.42E-05 
Table 2.5 Concentration of buffer species in carbonic acid system under normal 
atmosphere condition (PCO2=3.5 x 10-4 atm).  
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Postprandial GI lumen 
PCO2(37%atm/280mmHg/
37.49 kPa) 
pH   [HCO3-] (mM)   [HCO3-] (mM)   [HCO3-] (mM) 
5.0 5.13E-04 7.33E-02 5.40E-01 
5.5 1.62E-03 2,32E-01 1.71E00 
6.0 5.13E-03 7.33E-01 5.40E00 
6.8 3.24E-02 4.63E00 3.41E01 




Figure2.5 Transport of bicarbonate at gastrointestinal epithelial cell summarized 
from  (96) (100, 105)  
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CHAPTER III. CHOICE OF BUFFER FOR PHYSIOLOGICAL RELEVANT 




Developing proper in vitro dissolution tests for weak acid drugs are important for 
establishing in vitro- in vivo correlations and better bioequivalence tests. Factors from 
both dissolution media and drug properties are important and interact with each other 
in determining the drug release from the dosage form. This study investigates the 
effect of buffer factors and drug properties on the intrinsic dissolution test to improve 
the in vitro dissolution media with the aim of more closely reflecting physiological 
dissolution. 
 
Intrinsic dissolution tests of model NSAIDS drug, ibuprofen, have been performed in 
buffers with different pHs, buffer strengths in physiological bicarbonate buffer and 
USP acetate buffer. Two mass transport models, reaction plane model and film model 
were developed using Mathematica® and Matlab® to simulate the buffer and drug 
species effects on dissolution. Simulations were performed with buffer parameters 
changing including buffer strength, buffer species, pH. The effects of drug properties 
such as solubility, pKa and diffusion coefficient were also determined and compared 
with experimental intrinsic dissolution tests.  
 
The two models agreed well and can be used to predict the intrinsic dissolution rate of 
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the drugs. Buffer factors, including buffer strength, species and pH, affected the rate 
of dissolution when being changed. Both Models were sensitive to drug properties 
especially drug pKa. 
 
Buffer species can significantly impact the dissolution rate of weak acid drugs. 
Comparing the different buffers with bicarbonate buffer, we could establish a 
correspondence between buffers that can be used in in vitro testing and suggest a more 




With the implementation of FDA guidance of “Waiver of In Vivo Bioavailability and 
Bioequivalence Studies for Immediate Release Solid Oral Dosage Forms based on 
biopharmaceutical class”(16, 17), developing an proper in-vitro dissolution test 
became more critical for reflecting in vivo dissolution the drug product, further 
evaluating the drug performance in human body. The in vivo dissolution process is an 
interaction of drug properties including physiochemical, dosage factors with 
gastrointestinal fluid and its hydrodynamics. The drug properties are usually 
extensively studies during development while the gastrointestinal fluid and its proper 
surrogate media are still under investigation. The determination of simple buffer that 
could be used for dissolution test is not only useful for bioequivalence standard but 
also plays an important role earlier in development for selecting of formulations. 
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For BCS I and III drugs, with their high solubility, the bioavailability are not reply on 
formulation characteristics. For BCS II drugs, however, the drug absorption is 
dissolution limited, thus to establish an meaningful in vivo- in vitro correlation could 
be expected and the key is to develop an in vitro dissolution method reflecting the in 
vivo situation. The failure of developing IVIVC for nonsteroidal anti-inflammatory 
drugs (NSAIDs), could due to the dissolution media used for dissolution testing 
having large discrepancy with human intestinal fluid. NSAIDs are commonly 
recommended to be taken after meals. The current used dissolution media at 
postprandial pH are listed in Table 3.1. There are also continuous research on 




When using in vitro testing to predict the in vivo situation, a lot of factors that 
involving in translating in vivo to in vitro need to be considered. The direct using the 
human intestinal fluid could predict the in vivo drug dissolution more precisely(59). 
However, the huge cost and complicated procedure associated with the collection of 
fluid make it unrealistic use in industrial setting. Even when taking the human 
intestinal fluid from in vivo to ex vivo, there are factors changing and information 
missing that may affect the correct predication of drug performance physiologically. 
 
In this study, we investigated the dissolution of BCS II weak acidic drug, using 
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ibuprofen as a model NSAIDs drug, in USP acetate buffers and physiological 
bicarbonate buffers. Two mathematical models, buffered diffusion film model and 
reaction plane model were also utilized and refined to explain pH, the buffer strength 
and species difference interactions with drug physiochemical properties including 
pKa, solubility and diffusivity. With these efforts, the possibility of developing a 
physiological equivalent simple buffer system for drugs with known physiochemical 




Materials: ibuprofen was purchased from Acros Organics (Morris Plains, NJ), sodium 
chloride, sodium bicarbonate, sodium acetate and other chemicals of analytical grade 
were purchased from Sigma (St.Louis, MO). Distilled/deionized water was prepared 
using Milli-Q water (Millipore, Bedford, MA). 100% dried CO2 was purchased from 
lifeGas (Ann Arbor, MI).  
 
 
Establishing saturated bicarbonate buffer at normal atmosphere  
Different concentrations of sodium bicarbonate buffers were prepared at normal 
atmosphere and room temperature, and adjusted to isotonic using sodium chloride. 
Compressed CO2 was continuous purged into the buffers and the lowest pHs that the 





pH effect on ibuprofen intrinsic dissolution rate in bicarbonate buffer  
The rotating disk apparatus was based on Levich method(107) as in Figure 3.2, and 
consisted of a jacketed reactor maintained at 37°C. 1mM bicarbonate buffer was 
prepared isotonic with sodium chloride. CO2 was purged into buffer and reached the 
pH desired before experiments and maintained pH during experiments at pH 5.0, 6.0, 
6.8 by adjusting the CO2 flow rate. The 200mL buffer was placed into the reactor and 
a pH electrode was placed into the buffer. The drug disks were prepared with 200mg 
of bulk drug and compressed with 2000 lbs pressure for 60 seconds. The drug disk 
was attached to a shaft driven by a motor. The rotating speed was set at 100rpm. The 
disk was immersed into the medium when experiment started. The Agilent UV 
spectrometer (Santa Clara, CA) was set to measure the bulk buffer ibuprofen 
concentrations at 220nm through flow cell circulating the medium from the reactor. 
The intrinsic dissolutions of ibuprofen were performed at different pHs. Each 




Acetate buffer strength effect on ibuprofen intrinsic dissolution rate 
 
Simulated gastric fluids (SGF) of pH 1.2 without pepsin were prepared following the 
USP standards. Sodium acetate buffers were prepared isotonic with sodium chloride 
from 0mM to 50mM. pH of the buffers were adjusted to 5.0 using hydrogen chloride 
acid. The intrinsic dissolution tests of ibuprofen were performed in 200mL buffer at 
 48
37°C with disk rotating speed of 100rpm.The disk were prepared in the same 




Two mathematical models, reaction plane model and film model were utilized to 
model the dissolution of model drug, ibuprofen in buffers of different buffer strengths 
at different pHs.  
 
Reaction Plane Model: 
 
Reaction plane model is convective diffusion model different than film model in 
separating the fast reaction process in a thin “reaction plane” in boundary layer from 
the rate limiting process, thus the reaction process could be introduced as the flux 
boundary conditions of diffusive and convention process (62, 74, 108). In this study, 
the model was further refined to more accurately describe the buffer effect on acidic 
drug dissolution. The general continuity equation Eqn.1 is reduced to Eqn.2 when 










2∇ ---diffusive flux of species i, 
ic∇ν ---convective amount of species i 










cdD iii −= 2
2
------Eqn.2 
where ic is the molar concentration of the species і, t is the time, iD is the diffusion 
coefficient of species i, v is the fluid velocity. In Eqn.2, the mass transfer in rotating 
disk system could be simplified as one-dimension diffusion and convection along 
axial z. 
 





ci . Litt and Serad(109) showed that Eqn.2 could be further simplified into 
an ordinary differential equation Eqn.3 by introducing the dimensionless distance 
variable n for the axial distance z and defining the dimensionless dependent variables 
as following:  
ν
ωzn =  














nV z=)(  
i
i D
vSc =  
Cib and Ci0 are the molar concentration of species i in the bulk solution and at the 
solid-liquid interface, )(nCin  is the dimensionless concentration of species i at 
position n, vz is the axial velocity of the fluid that could be expended using the first 
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term of [ -( ωv )1/2(0.510n2 - 0.333n3 +...)]. )(nV  is the dimensionless velocity of the 











At the surface of the disk (n=0), the reversible reactions occur as below: 
−+ +⎯→← AHHA
A
aK  ------Eqn 4 
−+ +⎯→← BHHB
B
aK  ------Eqn 5 
−+ +⎯→← OHHOH WK2 ------Eqn 6 
−− +↔+ AHBBHA ------Eqn 7 
−− +↔+ AOHOHHA 2  ------Eqn 8 
−− +↔+ BOHOHHB 2 ------Eqn 9 
Three of them are independent, the mathematical expressions could be represented by 
Eqn 3 with i =HA, A-, H+, HB, 
 
Applying the boundary conditions at n=0(surface): CHA==1,CH=1,CA=1,CHB=1 
and the boundary condition at n=∞ (bulk solution): CHA=0,CH=0,CA=0,CHB=0 
 
The solution to Eqn.3 is  
∫ ∫∫ ∫−=
∞




ii dnVdnScVdnScnC ------Eqn 10. 
Differentiating Eqn 10 and using first term of the velocity series expansion as Levich 







In pH region of pH≤ AapK  -1 and pH≤
B
apK -1, ionization of HA and HB and the 
reaction of HA with B- and OH- are limited. So the total molar flux from the surface is 
N0=JHA= - 3/10 )(][ HAHA ScHADν
ω  ------Eqn 11 
With the pH increases, the ionization and reactions become significant at the surface, 
the total drug flux 








ω  ------Eqn 12 




















+=+=  ------Eqn 13 
allows the comparison of drug flux in different buffers once the 0HC  is solved. α =1 
when diffusion coefficient of HA and A- are equal. 
From the Eqn 4-6, the following flux equation holds since for every molar H+ 
produced, there is either a molar of A- , B-or OH- produced. Also A- , B- and OH- 
conserve in between either two of them in Eqn 7-9. 
So,  
NH = NA +NB + NOH------Eqn 14 
Where NH is the molar flux of H+, NA is the molar flux of A-, NB is the molar flux of B-, 










OHBAH CCDCCDCDCCD )()()( 0000 −+−+=−  
------Eqn 15 
The total concentration of buffer is CT=CBn+CHBn. Assuming Levich gradients for all 














































In Eqn 16, the ionization constant of drug, AaK and buffer 
B
aK are known, Schmidt 
number of A-, HA,H+,B-,OH- could be calculated from their diffusion coefficient in 
buffer, intrinsic solubility of the drug 0][HA is known for specific drug and total 
buffer concentration TC  and pH ( HbC ) are also known in certain buffer system. So 
the Equation could be solved using Mathmatica ® with the only unknown 0HC . Then, 
N/N0 could be determined using Eqn 13 to see the buffer effect on drug dissolution.  
 
Film Model: 
The first model is a homogeneous chemico-diffusion film model developed and 
applied to drug dissolution describing the drug diffusing and reacting with other ion 
species from bulk buffer throughout the stagnant film adjacent to the solid-liquid 
surface (64, 72, 73, 110). In our system, the weak acidic drug dissolves and 
dissociates into ionized form when pH is higher at the solid-liquid surface and 
diffuses and react with buffer species all across the boundary layer. At steady state, 
the reactions described in Eqn 4-9 occur in the boundary layer, similarly Eqn 14 
preserves. Also, when closely observing the reactions in Eqn 4-9 the following 
relationships could be established: 
 
NH+NHA = NOH+NB -----Eqn 17 
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Because from Eqn 5 and 6, for every molar H+ generated, there is either a molar B- or 
OH- generated along with it. Similarly from Eqn 7 and 8, we see the same situation 
for every molar of HA. Eqn 4 and 9 describe that terms in either end of Eqn 17 are in 
equilibrium between themselves.   
By comparing Eqn 14 and Eqn 17, we get  
NHA= - NA -----Eqn 18 
 
Eqn 18 presents that the weak acid drug is either in unionized form or ionized form. 
Similarly for buffer species, we have  
 
NB= - NHB-----Eqn 19 




∂ = - 2
2
dz
cdD ii  to each term of Eqn 17-19, and apply boundary 
conditions: 
 at z=0, CHA= CHA0= [HA]0, ,CH= CH0,CA= CA0,CHB= CHB0, CB= CB0, COH= COH0 
and the boundary condition at z=h (bulk solution): CHA= CHAh≈0,CH= CHh ,CA= CAh≈0, 
CHB= CHBh, CB= CBh, COH= COHh.  
The concentrations at the bulk solution and the intrinsic solubility of HA is known, 
others are unknown.  
 
The final equation could be reduce to a single equation with only CH0 as unknown 


















aB KDDHAKDDbaKDr −−−= 0][)(  
HhHBhBOHhOH CDCDCDa −+=  
HBhHBBhB CDCDb +=  
 
Once CH0 could also be solved using Mathmatica ®, the other unknowns could also be 
easily calculated.  
 
The negative total acid flux at z=0 is the drug dissolution rate  
N= (NA NHA+) = (NHA+NH-NB-NOH) 
= 1/h[DHA [HA]0+DH(CH0-CHh)-DB(CB0-CBh)-DOH(COH0-COHh) -----Eqn 21 
Similarly with reaction plane model, we take ratio of this drug flux with the drug flux 
in low pH where only drug flux is in unionized form: 
N0 = 1/h[DHA [HA]0] 
N/ N0= 1+[DH(CH0-CHh)-DB(CB0-CBh)-DOH(COH0-COHh))/ DHA [HA]0] 
The assumption here is no difference in the boundary layer thickness h the same drug.  
h= 1.612 D1/3ν 1/6ω -1/2 
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Model parameters selection: 
 
The parameters selected to be used in the reaction plane model and film model are 
listed in Table 3.2, including drug properties such as diffusion coefficient, pKa and 
intrinsic solubility, also, buffer species properties like diffusion coefficient of ionized 
and unionized forms, pKa.  
(Table 3.2) 
 
The carbonic acid buffer system could be more accurately described as below 
(111-115): 
−+−+ +⎯→←+⎯→←⎯→←+⎯→← 23332222 2.)()( 21
'
COHHCOHCOHOHaqCOgasCO aadc KKKK
The equilibrium constant is 
22
'
/][/1 PCOCOKK hc == ,  
where molatmLKh /41.29 •= is Henry’s law constant for CO2 at 25C. Kd= 1.6 x 
10-3, Ka1=2.72 x 10-4 and Ka2=5.61 x 10-11 at 25C with corresponding pKa1=3.57 p 
Ka2=10.25. At the experimental conditions, pH 5-6.8, carbonate presented only in 
trace amount, only pKa1 is considered. Ka =Kd* Ka1= 4.30 x 10-7gives the apparent 
pKa of carbonic acid 6.36. However, in our experimental conditions, the bicarbonate 
buffer is purged with CO2 before experiments and keep pH at certain pH by adjust the 
CO2 flow rate, the step with Kd is negligible and the step with Ka1 is the controlling 
step and the dissociation constant is more close to Ka1 which is used for model.  
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RESULTS: 
The saturated bicarbonate buffer could be established at pH5.0 only at low 
concentration of 1mM buffer strength at normal atmosphere pressure. The lowest pHs 





pH effect on ibuprofen intrinsic disk dissolution rate in bicarbonate buffer  
 
With the pH of the bulk 1mM isotonic bicarbonate buffer increased from 5 to 6.8, the 




The reaction plane model and film model discussed were tested over the same pH 
range in bicarbonate buffers. The initial drug flux ratios in buffers and in pH1.2 SGF, 
N/N0 are plotted in Figure 3.4. The agreement of the observed and predicted initial 
dissolution rates was good over the pH range of the bulk solution buffer. When  DA = 
DHA = 0.92 x 10-5 cm2/s, α = 1 was used, film model predicted more accurate at 
higher pH ends and reaction plane model predicted better at the lower pH end. In the 
situation where DA ≠ DHA,  DA was estimated using the equation of harmonic average 
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with DH and DHA, α = 1.54 and in both models, the predicting curves shifted towards 
the experimental data, and the reaction plane model was more close to experimental 
data at higher pH end and film model performed better at lower pH end. So the 
combination of these models would provide a best picture of the drug dissolution 
increased in bicarbonate buffers. 
(Figure 3.4) 
 
Acetate buffer strength effect on ibuprofen intrinsic dissolution rate 
 
Initial dissolution flux ratios predicted from models were compared with the 
experimental data in acetate buffers of different buffer strength. The results are 
showed in Figure 3.5. In Model 1, it was the assuming that DA = DHA and diffusion 
coefficient was constant in the experimental acetate concentrations. Film model and 
reaction plane model agreed well with each other and were very close to the 
experimental data. The models underestimated the flux ratio by just 7% at 50mM 
concentration of acetate buffer, and overestimated the flux ratio at 0mM isotonic 
solution by 28% due to the low absolute value. 
(Figure 3.5) 
 
Experimentally, acetate buffer of concentration 1.75mM were showed to have the 
equivalent drug dissolution flux ratio as 1.0mM bicarbonate buffer at pH5.0. The 




Model sensitivity analysis: 
 
To better provide suggestion of USP acetate buffer which could be equated to 
bicarbonate buffer, the sensitivity of the drug physiochemical properties were tested in 
50mM acetate buffer. The drug intrinsic solubility of 10-2 to 10-8 M, the drug pKa 
from 10-3 to 10-6, and the diffusion coefficient from 10-6 to 10-5 cm2/s were set to test.  
The drug pKa and intrinsic solubility effects on drug dissolution with the drug 
diffusion coefficient = 0.5 x 10-5 cm2/s were shown in Figure 3.6.  
(Figure 3.6) 
 
The buffer effect could increase the flux by 100 times compared with in SGF solution 
at solubility of 10-8 and pKa of 3. The increase dependence intrinsic solubility was 
larger at pKa 3.0 than 6.0, also the dependence on pKa was larger at lower than at 
higher intrinsic solubility.  
 
Similar test was done on drug diffusion coefficient and pKa with fixed intrinsic 
solubility of 1 x 10-4 cm2/s, also, on drug solubility and diffusion coefficient with 
fixed pKa = 4.0. The results were showed in Figure 3.7 and Figure 3.8. When drug 
intrinsic solubility was 10-4M, the drug flux ratio was increased from 1.1 when pKa is 




With pKa =4.0, changing of intrinsic solubility and diffusion coefficient of drug, the 
flux ratio could increase from 3.34 at the high solubility and high diffusion coefficient 




Buffer species can significantly impact the dissolution rate of weak acid drugs. The 
dissolution process could be well described by mathematical models such as reaction 
plane model and film model. Comparing USP acetate buffer with physiological 
bicarbonate buffer species, we could establish correspondence between buffers using 
models and the results were verified by experiments. The effect of drug 
physiochemical properties on the dissolution was also analyzed and could be utilized 
to develop the computational tools which providing the suggestions of the proper 
buffer strength to do the biorelevant dissolution test.  
 
For the best biowaiver test, the in vitro bioequivalence has to be designed to predict 
the drug products performance in vivo; the dissolution media has to reflect the in vivo 
gastrointestinal fluid to be predictive. The combination of theoretical work and 
experimental work here demonstrated a useful approach for a rational design of 
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dissolution media in terms of pH and buffer strength. The USP buffers which are more 
widely used in industry could be used and equated to physiological bicarbonate buffer 
when drug physiochemical properties are known.  
With an in vivo reflecting dissolution methodology, the biowaiver could be considered 
for BCS II poorly soluble acidic drugs.  
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Dissolution Media pH  Buffer composition 
United State Pharmacopeias 
(USP) buffer(116) 
 










4.5 50mM potassium dihydrogen phosphate 
 
Fed State Simulated Intestinal 
Fluid (FeSSIF)(106) 
 
5.0 144mM acetate buffer: 
Sodium taurocholate 15 mM 
Lecithin 3.75 mM 
NaOH (pellets) 4.04 g 
Glacial Acetic Acid 8.65 g 
NaCl 11.874 g 
Purified water qs. 1000 mL 
osmolality of about 670 mOsmol/kg. 







Figure 3.1 The structure of ibuprofen  
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Figure 3.2 Rotating disk apparatus studying bicarbonate buffers.  
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Table 3.2 Parameters used in theoretical analysis 
a. calculated by ADMET predictor (Simulations Plus, Lancaster)(120).b. calculated 
using harmonic average equation with DHA and DH+ c. data from (121) and corrected 
to 37C using Stokes-Einstein equation. d. using conductance data in (122) HCO3- 44.5 
cm2/Ω/equiv. calculated using D=2.662*10-6λi/Zi(121) and corrected to 37C with 
Stokes-Einstein equation 
substance D (x105) cm2/s pKa MW(g/mol) Intrinsic 
solubility (M) 
ibuprofen HA 0.92a /A-0.48b 4.42 (119) 206.28 2.38 x 10-4 
(119) 
CH3COOH 1.26d 4.60(64) 60.05  
CH3COO- 1.39c    
H2CO3 1.99c 3.57(114, 115) 62.03  
HCO3- 1.25(110)    
H+ 9.68c    














Table 3.3 The pH of CO2 saturated bicarbonate buffer at normal atmosphere and 
the room temperature. 
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Figure 3.3 The Initial ibuprofen dissolution rate in 1mM bicarbonate buffer with 
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Figure 3.4 Initial dissolution flux ratios predicted from models compare with the 
experimental data in bicarbonate buffer of different pHs. (a) Models 1 , DA = 
DHA = 0.92 x 10-5 cm2/s, α = 1 was used. (b) Models 2, α  = (DA / DHA) 2/3 = 
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Figure 3.5 Initial dissolution flux ratios predicted from models compare with the 
experimental data in acetate buffer of different buffer strength. (a) Models 1 , DA 
= DHA = 0.92 x 10-5 cm2/s, α = 1 was used. (b) Models 2, α  = (DA / DHA) 2/3 = 









1 mM Sodium 
Bicarbonate 
5.0 1.9190(0.13) 2.0563 
1.75mM Sodium 
Acetate 
5.0 1.7667(0.10) 1.9971 
SGF, 0.1N HCl 1.2 0.8846 (0.05) 1.0000 
 














































Figure 3.6 When drug diffusion coefficient is 0.5 x 10-5 cm2/s, the drug pKa and 
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Figure 3.7 When drug intrinsic solubility = 1 x 10-4 cm2/s, the drug pKa and 












































Figure 3.8 When drug pKa = 4.0, the drug intrinsic solubility and diffusion 
coefficient effects on drug dissolution rate in 50mM acetate buffer. 
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CHAPTER IV. THE EFFECT OF PHYSIOLOGICAL 
FACTORS ON BICARBONATE DISSOLUTION BUFFER 
 
Abstract 
Bicarbonate has been determined to be the dominant buffer species in human 
intestinal fluid and has a large effect on the drug dissolution. However, the 
bicarbonate buffer system is a much more complicated system than other buffer 
systems since the bicarbonate ions are always in equilibrium with carbonic acid, 
further with CO2 dissolved and water. The carbon dioxide dissolved in water is 
affected by the partial pressure of it in gas state which changes with different 
physiological and pathological status in gastrointestinal lumen. The formation of 
carbonic acid equilibrium is catalyzed by carbonic anhydrase which plays a central 
role in bicarbonate equilibrium in the gastrointestinal tract. These factors influence the 
bicarbonate buffer system and through it affect the dissolution of the ionizable acidic 
drugs. The intrinsic dissolution study of the model drug, ibuprofen is conducted with 
the bovine carbonic anhydrase in the bicarbonate buffers in the gastrointestinal 
physiological pH ranged from 5-6.8, and the results indicated the significant increase 
of dissolution rate. The effect of acidic drug dissolution in bicarbonate buffer in 
equilibrium with different partial pressure was also simulated by the mathematical 
models, reaction plane model and film model, to demonstrate that the partial pressure 




Bicarbonate buffer system is the major buffer in biological system regulating the 
acid-base balance. It is also the dominant buffer in gastrointestinal tract. There are 
many physiological factors could affect the dissolution of acidic drug through their 
effect on the buffer system. Carbonic anhydrase and partial pressure of CO2 are major 
factors involving in the bicarbonate equilibrium system. 
 
Carbonic anhydrase (CA) accelerate the reaction of CO2 hydration reversibly. It has 
the highest turnover number of molecules among all known enzymes. The carbonic 
anhydrase family has been divided into cytosolic CAs(CA I, CA II, CA VII, CA XIII), 
mitochondrial CAs( CA-VA, CA-VB), and membrane associated CAs(CA IV, CA IX, 
CA XII, CA XIV, and CA XV) (123-126). There are three additional CA isoforms (CA 
VIII, CA X, CA XI) whose function are unknown yet. Carbonic anhydrase II is the 
monomeric with molecular weight over 30KD. Since it is lack of side chain of 
cysteine, it requires no external cofactors and relatively stable against the oxidation 
and inhibition of heavy metals. Its solution could be extremely stable and retain 
enzymatic activity for weeks, also its mobilized form on solid matrix used in chemical 
reactors could allow the operation temperature close to 50 °C (127).  
 
Carbonic anhydrase has been shown widely distributed and has activities in various 
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segments of gastrointestinal tract (128, 129). The stomach and the colon showed high 
carbonic anhydrase activity, the jejunum had intermediate activity, and the ileum had 
low activity. There is also evidence showing the CA IV abundant available at the 
brush border in human GI.  CA VI has been shown by radioimmunoassay secreted in 
to saliva and tissue (130-132). Carbonic anhydrase facilities the secretion of 
bicarbonate to protect the GI tract(133), thus could also involving the bicarbonate 
equilibrium in intestinal fluid and affect the acidic drug dissolution process.  
 
Since bicarbonate system is open ended equilibrium with CO2. The partial pressure of 
CO2 in the head space of the bicarbonate could affect the system and push the 
equilibrium 
−+−+ +⎯→←+⎯→←⎯→←+⎯→← 23332222 2.)()( 21
'
COHHCOHCOHOHaqCOgasCO aadc KKKK
to the right end, and thus affect the acidic drug dissolution through the buffer system. 
In vivo, the resting PCO2 in lumen is 38mmHg (5 % atm), which is comparable to PCO2 
in arterial blood. Postprandial PCO2 could increase to 280mmHg (37%atm) with the 
extreme of 502mmHg (66% atm) (58, 89, 90, 134). In the duodenal ulcer patients, the 
partial pressure is even higher with average of 480mmHg, and some patient has 
700mmHg the reading from the plot of results (89). With higher physiological and 
pathological CO2 partial pressure, the concentration of bicarbonate is also expected to 
be higher than that under the normal atmosphere. PCO2 is likely to affect the acidic 
drug dissolution through its effect on the bicarbonate equilibrium.  
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In this section, intrinsic dissolution of ibuprofen with CA and mathematical models, 
film model and reaction plane model are used to illustrate the carbonic anhydrase 
enzymatic effect and the effect of partial pressure of CO2 on acidic drug dissolution. 
Experimental studies: 
Materials:  
ibuprofen was purchased from Acros Organics (Morris Plains, NJ), sodium chloride, 
sodium bicarbonate, sodium acetate and other chemicals of analytical grade were 
purchased from Sigma (St.Louis, MO). Distilled/deionized water was prepared using 
Milli-Q water (Millipore, Bedford, MA). 100% dried CO2 was purchased from 
lifeGas (Ann Arbor, MI). Carbonic anhydrase from bovine erythrocytes was 
purchased from MPbiomedicals (solon,OH) 
 
Methods:  
Rotating disk dissolution of ibuprofen with Carbonic anhydrase in bicarbonate 
buffer 
1mM NaHCO3 buffer was prepared isotonic with sodium chloride. CO2 was purged 
into 200 mL buffer in the rotating disk jacket beaker and reached the pH5.0, 5.5, 6.0, 
6.8 before experiments. 5mg Carbonic andydrase (enzymatic activity: 4580 u/mg 
solid) was added to the buffer until dissolved. The drug disks were prepared with 
200mg of bulk drug and compressed with 2000 lbs pressure for 60 seconds. The drug 
disk was attached to a shaft driven by a motor, speed was set at 100rpm. The disk was 
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immersed into the medium when the experiment started. The Agilent UV 
spectrometer (Santa Clara, CA) was set measuring the bulk buffer ibuprofen 
concentration at 220nm through flow cell circulating the medium from the reactor, 
blank was taken before the disk was immersed. Each experiment was run for 20min, 
and measurements were taken every one minute. The intrinsic dissolutions of 
ibuprofen were performed at different pH. Each experiment was done in triplicates 
and the initial drug fluxes from the disk surface were calculated. This is referred as 
“Group A experiments with CA and fixed pH”. 
 
For pH5.0, the same experiment was perform with carbonic anhydrase but only the 
initial pH was controlled, during the dissolution there was no CO2 sparing to maintain 
the pH, with the acidic drug dissolving pH increased during experimental process, but 
final pH recorded was no higher than 0.3 unit above the starting pH. 
“Group B experiments with CA, starting pH”. 
 
Rotating disk dissolution of ibuprofen without Carbonic anhydrase in 
bicarbonate buffer 
The same experiment with group A was done except without the step of adding 
carbonic anhydrase. The experiments were also done at pH5.0, 5.5, 6.0 and 6.8. Every 
experiment was run for 20min, and measurements are taken every one minute. Each 
experiment was done in triplicates and the initial drug fluxes from the disk surface 
were calculated. This is referred as “Group C experiments without CA and fixed pH”. 
 78
 
The controlled experiments of the group B were also done with no carbonic anhydrase 
added, and without CO2 sparing to maintain the pH and this group is referred as 
“Group D experiments without CA, starting pH”. The pH increased during the 
experiments was no larger than 0.38 pH unit from pH5.0.  
 
Theoretical studies: 
The partial pressure of CO2 on bicarbonate buffer was integrated in to the film model 
and reaction plane model discussed. Its effect on the dissolution model drug, 
ibuprofen was simulated and the ratio of drug flux in CO2 influenced bicarbonate 
buffer to that in the non-buffered solution is calculated.  
 
The partial pressure of CO2 values from the pressure in normal atmosphere to the 
possible highest reported value were used to calculate against the physiological GI pH 









cK = 29.76 atm/(mol/L) is the henry’s constant at 25 °C. 
−+ +⎯→←+ 322 .)( HCOHOHaqCO
Ka , 
Ka=6.1 at 37 °C. 
 
Figure 4.1 shows that the effect of pH and PCO2 on the concentration of bicarbonate in 
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physiological and pathological values reported. 
(Figure 4.1) 
 
The bicarbonate concentration at resting PCO2 could be 0.13mM to 8.42 mM, 
postprandial bicarbonate would increase from 0.9mM to 62mM with pH varies from 
pH5.0 to pH6.8, with the extreme incident of 1.76mM to 111mM. In duodenum ulcer 
patients, the bicarbonate could be very high with the average of 1.69mM to106mM 




The experiments showed that the effects of carbonic anhydrase in the bicarbonate 
buffer solution on the dissolution rate of acidic drug were significant across the 
different fixed pHs. The results are showed in Figure 4.2.  
(Figure 4.2) 
 
At pH5.0, both groups (A, B) with carbonic anhydrase showed the increased drug flux 
from the disk surface compared with the groups(C, D). But, since the absolute values 
were small due to the low concentration and pH, it was hard to differentiate the fluxes 
from group A, C, and D. In group B with carbonic anhydrase but no CO2 sparing, the 
effect of increasing weak acid drug dissolution rate was most significant. Although, 
since pH in group B was also increasing, the increased flux could partially be caused 
by the pH effect, the flux could still be larger than the flux of that in higher intial pH 
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buffer but without carbonic anhydrase. At this condition, without purging CO2 to 
control pH and with the enzymatic catalysis, the variation of experiment results was 
larger than at other conditions. 
  
In the equilibrium of −+ +⎯→←⎯→←+ 33222 1.)( HCOHCOHOHaqCO a
KCA  
Since carbonic anhydrase catalyzed the hydration reaction of CO2, with CO2 purging 
supply, according to LeChatelier's principle, the reaction is pushed towards the 
generation of bicarbonate. Since the effect of purging CO2 is also pushing the reaction 
towards the same direction, the enzymatic effect is more significant without the 
supply of CO2. Although the pH increased about 0.3 units, the flux of the drug release 
from the tablet increased is larger than that increased just by the pH effect. 
 
At higher pH, with the CO2 sparging to maintain the pH, the fluxes were increased by 
the adding of the carbonic anhydrase. When pH is 6.8, the increase was the most 
significant and almost doubled the rate without CA. Since it is reported that the 
enzymatic activity of CA is higher in pH 7.5 compared with 5.5(135), also at alkaline 
pH higher pH accompanied by higher activity (136), the increased activity of the flux 
may also be explained by the increased CA activity.  
 
The effect of bicarbonate buffers under the effect of physiological and pathological 
PCO2 on the dissolution of ibuprofen was simulated by reaction plane model and film 
model. The ibuprofen dissolution flux ratios in buffered verse unbuffered bicarbonate 
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solutions were listed in Table 4.1 and 4.2. At duodenal resting PCO2, the drug flux in 
bicarbonate buffer increase about 2-4 times compared with non-buffered solution 
across the pH5.0-6.8. At postprandial duodenal PCO2, the drug flux increased from 
about 2 times at pH5.0 to about 8 or 10 times at pH6.8 compared non-buffered 
solution.  
( Table 4.1) 
( Table 4.2) 
Discussions 
The consideration of the physiological and pathological factors in gastrointestinal 
tract is essential for in vivo-in vitro correlation for the drug absorption. These factors 
could affect the dissolution process directly, or through their effects on the drug 
dosage forms, and also could be involved in the dissolution media, since the 
dissolution process is ultimately the drug molecule mass transfer between delivery 
system and the biological fluid under the physiological and/or pathological 
hydrodynamics.  
 
The key factors involved in bicarbonate system equilibrium was investigated and 
demonstrated to affect the acidic drug dissolution. The pH, buffer species, partial 
pressure of CO2, and also carbonic anhydrase constitute a complicated buffer system 
itself without other factors like bile salts, protein, etc. More knowledge is needed to 
fully understand this system such as the input rate of bicarbonate or CO2 that is 
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physiologically relevant, the amount of carbonic anhydrase that functions in the 
bicarbonate buffer system and so on. However, capturing the key parameters in this 
bicarbonate system with the aid of computational method would lead us to more 
understanding and further utilizing this system as dissolution media for testing drug in 
vivo performance. 
There are also pathological conditions that could result in different level of absorption 
of poorly soluble drug. In clinical, for duodenal ulcer patients, NSAIDs are suggested 
to be avoided because its GI irritation side effect. From our study, we can see 
pathological PCO2 would affect the poorly soluble ionisable drugs including NSAIDs, 
so serious considerations should be given when considering the use of drug under 





1. Duodenal resting (fasted) CO2 partial pressure.  
2. Duodenal postprandial (fed) CO2 partial pressure. 
3. Extremely high duodenal postprandial CO2 partial pressure. 
4. Duodenal ulcer CO2 partial pressure. 
5. Extremely high duodenal ulcer CO2 partial pressure  
 













































Dissolution of Ibuprofen in 1mM isotonic NaHCO3 solution
pH


















without CA, fixed pH(group C)
with 0.025mg/ml CA, fixed pH(group A)
without CA ,starting pH(group D)
with 0.025 mg/ml CA, starting pH(group B)
 
Figure 4.2 Enzymatic effect of carbonic anhydrase on the dissolution of acidic 



























1.83 2.10 2.26 2.27 2.41 
5.5 
2.03 2.80 3.23 3.27 3.60 
6 
2.40 4.14 5.03 5.10 5.78 
6.8 
4.03 8.97 11.36 11.59 13.47 
Table 4.1 Reaction plane model simulated ibuprofen dissolution flux ratios in 


























5 2.14 2.35 2.50 2.51 2.63 
5.5 2.39 3.13 3.57 3.61 3.96 
6 2.77 4.61 5.58 5.66 6.41 
6.8 4.52 10.04 12.74 12.95 15.12 
Table 4.2 Film model simulated ibuprofen dissolution flux ratios in bicarbonate 
buffer under physiological and pathological PCO2 
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CHAPTER V. SUMMARY 
 
The in vitro dissolution test is important for quality control, formulation development 
and for bioequivalence tests. However, designing the proper dissolution test to closely 
reflect the in vivo dissolution process is difficult because the complexity of 
gastrointestinal physiological and logical factors, the drug physiochemical factors, the 
factors involved making the drug into final product and their interactions with each 
other. The developing of the dissolution methods could be advanced when more 
information about above factors becoming available. The key factors then could be 
identified and utilized in the refining of the methodology. The dissolution media is 
one of the most important issues among all the factors and is studied here.  
 
The research in this dissertation provides more information on the physiological 
buffer species, bicarbonate buffer in real human intestinal fluid in terms of its buffer 
capacity and its effect on dissolution of acidic drugs. The results showed that at 
physiological pH range 5.0-7.0, bicarbonate contribution to the buffer capacity of 
fasted ex vivo whole human intestinal fluid was larger than 50%. The intrinsic 
dissolution rate of BCS II acidic drug in human intestinal fluid reduced 48% when 
bicarbonate buffer been depleted from the fluid; The concentration of HCO3-/CO2 
buffer determined by titration was 4.5 mM, which was consistent with the IC results 
of 4.3 mM for bicarbonate and only 0.62 mM for phosphate. These studies suggested  
the importance of the physiological in vivo buffer, bicarbonate buffer, when 
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considering the choice of buffer species for the in vitro dissolution test. Furthermore, 
a miniature rotating disk apparatus has been demonstrated to be useful when the 
dissolution media or active pharmaceutical ingredient is limited.  
 
Since the pharmacopeial buffers have been widely used in pharmaceutical industry 
with different types of dissolution apparatus, it is meaningful to determine the 
physiological equivalent compendial buffer. Through the analysis of reaction plane 
and film models in our work, the relationships among different buffer species and 
strength effect on the dissolution of a BCS II acidic drug was predicted and has been 
verified by experimental results; Models built in mathematica® and Matlab® can also 
be developed into a tool to provide suggestions on compendial buffer strength with 
the drugs of known physiochemical properties. 
 
The other physiological factors including partial pressure of CO2 and carbonic 
anhydrase would also affect the in vivo dissolution process through their effect on the 
physiological buffer media. In this work, carbonic anhydrase and partial pressure of 
CO2 were investigated since they both play critical roles in the equilibrium in the 
bicarbonate systems. With enzymatic effect of carbonic anhydrase, the dissolution 
rate of BCS II acidic drug, ibuprofen increased significantly at pH5.0-6.8.The reaction 
plane and film models showed that the increase of partial pressure of CO2 at 
physiological and pathological range would    o increase the dissolution of BCS II 
acidic drug. The theoretical approach can assist us to analyze the in vivo situation 
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more closely when the experimental conditions are difficult to set.  
 
While bridging the in vitro to in vivo dissolution is a desirable goal, there are many 
gaps in our knowledge that need to be filled to completely understand and develop 
media reflecting the in vivo situation as showed in Figure 5.1. 
 (Figure 5.1) 
1. From the in vivo human intestinal fluid to ex vivo human intestinal fluid: the 
collection site in different segments along the intestinal tract; the technique used 
will generate differences in between human intestinal fluids in vivo and ex vivo. 
Since experimental interference and partial pressure over the fluid is changed 
once the fluid is outside the body, the pH increase as CO2 evaporates from the 
fluid. The flow velocity of the fluid, the transit time, temperature, also the 
gastrointestinal dynamics information are lost in between the in vivo and ex vivo 
human intestinal fluids. There are also studies using canine intestinal fluid as the 
substitute of humans, but there are many species differences to be considered(25).  
2. From the ex vivo human intestinal fluid to physiological bicarbonate buffer, there 
are a lot of factors should be considered to overcome the gap in between these 
fluids, such as viscosity, volume, surface tension of the dissolution media, also 
exogenous and endogenous substances like enzymes, bile salts, protein, lipids in 
the fluid. The biorelevant FaSSIF and FeSSIF buffers proposed by Dressman et.al 
(106, 116, 137, 138) are in the correct route of thinking in this aspect. 
3. When correlating the physiological bicarbonate buffer to simple pharmacopoeial 
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buffers in vitro, the buffer species and strength differences could be considered 
together with the drug physiochemical properties such as pKa, diffusion 
coefficient, solubility etc.  
 
The research presented here focused on several of above gaps and made a solid step in 
the rational design of in vitro dissolution methods. With the combination of the 
experimental and theoretical considerations, we are in the process of identifying the 
essential parameters in the in vivo process of dissolution of BCS II acidic drugs and 
developing the proper in vitro dissolution tests that will reflect the in vivo 
circumstance better.  
 91
  






1. L.J. Leeson. Product dissolution methods. J Pharm Sci. 62:IV (1973). 
2. C. Tong, S.S. D'Souza, J.E. Parker, and T. Mirza. Commentary on AAPS Workshop : 
Dissolution Testing for the Twenty-first Century: Linking Critical Quality Attributes and 
Critical Process Parameters to Clinically Relevant Dissolution. Pharm Res (2007). 
3. P.A. Dickinson, W.W. Lee, P.W. Stott, A.I. Townsend, J.P. Smart, P. Ghahramani, T. 
Hammett, L. Billett, S. Behn, R.C. Gibb, and B. Abrahamsson. Clinical relevance of 
dissolution testing in quality by design. Aaps J. 10:380-390 (2008). 
4. Guidance for Industry. Dissolution Testing of Immediate Release of Solid Oral Dosage 
Forms.  (1997). 
5. Guidance for Industry: Extended Release Solid Oral Dosage Forms: Development, 
Evaluation and Application of In Vitro/In Vivo Correlations. In U.S.D.o.H.a.H. Services, 
F.a.D. Administration, and C.f.D.E.a.R. (CDER) (eds.), Rockville, MD, 1997. 
6. V.R. Uppoor. Regulatory perspectives on in vitro (dissolution)/in vivo (bioavailability) 
correlations. J Control Release. 72:127-132 (2001). 
7. S. Dutta, Y. Qiu, E. Samara, G. Cao, and G.R. Granneman. Once-a-day extended-release 
dosage form of divalproex sodium III: development and validation of a Level A in 
vitro-in vivo correlation (IVIVC). J Pharm Sci. 94:1949-1956 (2005). 
8. E. Jantratid, V. De Maio, E. Ronda, V. Mattavelli, M. Vertzoni, and J.B. Dressman. 
Application of biorelevant dissolution tests to the prediction of in vivo performance of 
diclofenac sodium from an oral modified-release pellet dosage form. Eur J Pharm Sci. 
37:434-441 (2009). 
9. I. Kovacevic, J. Parojcic, I. Homsek, M. Tubic-Grozdanis, and P. Langguth. Justification 
of Biowaiver for Carbamazepine, a Low Soluble High Permeable Compound, in Solid 
Dosage Forms Based on IVIVC and Gastrointestinal Simulation. Mol Pharm (2008). 
10. N.B. Modi, A. Lam, E. Lindemulder, B. Wang, and S.K. Gupta. Application of in vitro-in 
vivo correlations (IVIVC) in setting formulation release specifications. Biopharm Drug 
Dispos. 21:321-326 (2000). 
11. N. Sirisuth, L.L. Augsburger, and N.D. Eddington. Development and validation of a 
non-linear IVIVC model for a diltiazem extended release formulation. Biopharm Drug 
Dispos. 23:1-8 (2002). 
12. P. Veng-Pedersen, J.V. Gobburu, M.C. Meyer, and A.B. Straughn. Carbamazepine 
level-A in vivo-in vitro correlation (IVIVC): a scaled convolution based predictive 
approach. Biopharm Drug Dispos. 21:1-6 (2000). 
13. S.H. Haidar, B. Davit, M.L. Chen, D. Conner, L. Lee, Q.H. Li, R. Lionberger, F. 
Makhlouf, D. Patel, D.J. Schuirmann, and L.X. Yu. Bioequivalence approaches for 
highly variable drugs and drug products. Pharm Res. 25:237-241 (2008). 
14. K.K. Midha, M.J. Rawson, and J.W. Hubbard. The bioequivalence of highly variable 
drugs and drug products. Int J Clin Pharmacol Ther. 43:485-498 (2005). 
15. J.E. Polli. In vitro studies are sometimes better than conventional human 
pharmacokinetic in vivo studies in assessing bioequivalence of immediate-release solid 
 93
oral dosage forms. Aaps J. 10:289-299 (2008). 
16. G.L. Amidon, H. Lennernas, V.P. Shah, and J.R. Crison. A theoretical basis for a 
biopharmaceutic drug classification: the correlation of in vitro drug product dissolution 
and in vivo bioavailability. Pharm Res. 12:413-420 (1995). 
17. Guidance for Industry. Waiver of In Vivo Bioavailability and Bioequivalence Studies for 
Immediate Release Solid Oral Dosage Forms Based on a Biopharmaceutics 
Classification System, Food Drug Administration, U.S. Department of Health and 
Human Services, Center for Drug Evaluation and Research. Washington D.C., 2000. 
18. D.M. Oh, R.L. Curl, and G.L. Amidon. Estimating the fraction dose absorbed from 
suspensions of poorly soluble compounds in humans: a mathematical model. Pharm Res. 
10:264-270 (1993). 
19. E. Merisko-Liversidge, G.G. Liversidge, and E.R. Cooper. Nanosizing: a formulation 
approach for poorly-water-soluble compounds. Eur J Pharm Sci. 18:113-120 (2003). 
20. M. Perrut, J. Jung, and F. Leboeuf. Enhancement of dissolution rate of poorly soluble 
active ingredients by supercritical fluid processes. Part II: Preparation of composite 
particles. Int J Pharm. 288:11-16 (2005). 
21. E.H. Storer, D.T. Dodd, P.A. Snyder, and C.O. Eddlemon. A telemetering capsule for 
gastrointestinal pH measurement. JAMA. 178:830-831 (1961). 
22. S.J. Rune. An electrode for pH measurement in the gastrointestinal tract. Scand J 
Gastroenterol. 3:91-94 (1968). 
23. J.M. Rawlingsand M.L. Lucas. Plastic pH electrodes for the measurement of 
gastrointestinal pH. Gut. 26:203-207 (1985). 
24. A.I. Khazanov, A.S. Ivlev, and S.A. Novoselets. [Apparatus for the multichannel pH 
measurement of the upper section of the gastrointestinal tract]. Med Tekh:27-28 (1978). 
25. C.Y. Lui, G.L. Amidon, R.R. Berardi, D. Fleisher, C. Youngberg, and J.B. Dressman. 
Comparison of gastrointestinal pH in dogs and humans: implications on the use of the 
beagle dog as a model for oral absorption in humans. J Pharm Sci. 75:271-274 (1986). 
26. V. Balazsand V. Varro. [Bactericidal Effects of Various Gastrointestinal Secretions with 
Acid Ph.]. Med Exp Int J Exp Med. 10:315-320 (1964). 
27. A.G. Press, I.A. Hauptmann, L. Hauptmann, B. Fuchs, M. Fuchs, K. Ewe, and G. 
Ramadori. Gastrointestinal pH profiles in patients with inflammatory bowel disease. 
Aliment Pharmacol Ther. 12:673-678 (1998). 
28. C.A. Youngberg, R.R. Berardi, W.F. Howatt, M.L. Hyneck, G.L. Amidon, J.H. Meyer, 
and J.B. Dressman. Comparison of gastrointestinal pH in cystic fibrosis and healthy 
subjects. Dig Dis Sci. 32:472-480 (1987). 
29. J. Fallingborg. Intraluminal pH of the human gastrointestinal tract. Dan Med Bull. 
46:183-196 (1999). 
30. P.C. Gregory. Gastrointestinal pH, motility/transit and permeability in cystic fibrosis. J 
Pediatr Gastroenterol Nutr. 23:513-523 (1996). 
31. Y. Sasaki, R. Hada, H. Nakajima, S. Fukuda, and A. Munakata. Improved localizing 
method of radiopill in measurement of entire gastrointestinal pH profiles: colonic 
luminal pH in normal subjects and patients with Crohn's disease. Am J Gastroenterol. 
92:114-118 (1997). 
32. J. Fallingborg, L.A. Christensen, M. Ingeman-Nielsen, B.A. Jacobsen, K. Abildgaard, 
 94
H.H. Rasmussen, and S.N. Rasmussen. Gastrointestinal pH and transit times in healthy 
subjects with ileostomy. Aliment Pharmacol Ther. 4:247-253 (1990). 
33. G. Brunner, P. Luna, and C. Thiesemann. Drugs for pH control in upper gastrointestinal 
bleeding. Aliment Pharmacol Ther. 9 Suppl 1:47-50 (1995). 
34. T. Zimmermannand M. Leitold. The influence of food intake on gastrointestinal pH and 
gastric emptying time. Experience with two radiotelemetering methods: (Heidelberg pH 
capsule system and Flexilog 1010). Int J Clin Pharmacol Ther Toxicol. 30:477-478 (1992). 
35. T.L. Russell, R.R. Berardi, J.L. Barnett, L.C. Dermentzoglou, K.M. Jarvenpaa, S.P. 
Schmaltz, and J.B. Dressman. Upper gastrointestinal pH in seventy-nine healthy, elderly, 
North American men and women. Pharm Res. 10:187-196 (1993). 
36. D.F. Evans, G. Pye, R. Bramley, A.G. Clark, T.J. Dyson, and J.D. Hardcastle. 
Measurement of gastrointestinal pH profiles in normal ambulant human subjects. Gut. 
29:1035-1041 (1988). 
37. J. Jinno, D. Oh, J.R. Crison, and G.L. Amidon. Dissolution of ionizable water-insoluble 
drugs: the combined effect of pH and surfactant. J Pharm Sci. 89:268-274 (2000). 
38. J.J. Sheng, N.A. Kasim, R. Chandrasekharan, and G.L. Amidon. Solubilization and 
dissolution of insoluble weak acid, ketoprofen: effects of pH combined with surfactant. 
Eur J Pharm Sci. 29:306-314 (2006). 
39. R. Tomita, S. Fujisaki, K. Tanjoh, and M. Fukuzawa. Studies on gastrointestinal 
hormone and jejunal interdigestive migrating motor complex in patients with or without 
early dumping syndrome after total gastrectomy with Roux-en-Y reconstruction for 
early gastric cancer. Am J Surg. 185:354-359 (2003). 
40. R. Tomita. Relationship between interdigestive migrating motor complex and gut 
hormones in human. Hepatogastroenterology. 56:714-717 (2009). 
41. H.S. Ormsbee, 3rd, G.L. Telford, and G.R. Mason. Required neural involvement in 
control of canine migrating motor complex. Am J Physiol. 237:E451-456 (1979). 
42. N.S. Hakim, N.J. Soper, M.P. Spencer, and M.G. Sarr. Role of extrinsic and intrinsic 
nerves in hormonal induction of the migrating motor complex in the jejunum. J Invest 
Surg. 2:437-446 (1989). 
43. G. Vantrappen, J. Janssens, T.L. Peeters, S.R. Bloom, N.D. Christofides, and J. 
Hellemans. Motilin and the interdigestive migrating motor complex in man. Dig Dis Sci. 
24:497-500 (1979). 
44. S.K. Sarna. Cyclic motor activity; migrating motor complex: 1985. Gastroenterology. 
89:894-913 (1985). 
45. G. Vantrappen, J. Janssens, J. Hellemans, and Y. Ghoos. The interdigestive motor 
complex of normal subjects and patients with bacterial overgrowth of the small intestine. 
J Clin Invest. 59:1158-1166 (1977). 
46. C.P. Dooley, C. Di Lorenzo, and J.E. Valenzuela. Variability of migrating motor complex 
in humans. Dig Dis Sci. 37:723-728 (1992). 
47. R.L. Oberle, T.S. Chen, C. Lloyd, J.L. Barnett, C. Owyang, J. Meyer, and G.L. Amidon. 
The influence of the interdigestive migrating myoelectric complex on the gastric 
emptying of liquids. Gastroenterology. 99:1275-1282 (1990). 
48. J.H. Szurszewski. A migrating electric complex of canine small intestine. Am J Physiol. 
217:1757-1763 (1969). 
 95
49. C.F. Codeand J.A. Marlett. The interdigestive myo-electric complex of the stomach and 
small bowel of dogs. J Physiol. 246:289-309 (1975). 
50. W. Woodtliand C. Owyang. Duodenal pH governs interdigestive motility in humans. Am 
J Physiol. 268:G146-152 (1995). 
51. B.A. Schurizek, K. Kraglund, F. Andreasen, L.V. Jensen, and B. Juhl. Gastrointestinal 
motility and gastric pH and emptying following ingestion of diazepam. Br J Anaesth. 
61:712-719 (1988). 
52. K.A. Rao, E. Yazaki, D.F. Evans, and R. Carbon. Objective evaluation of small bowel 
and colonic transit time using pH telemetry in athletes with gastrointestinal symptoms. 
Br J Sports Med. 38:482-487 (2004). 
53. D. Horterand J.B. Dressman. Influence of physicochemical properties on dissolution of 
drugs in the gastrointestinal tract. Adv Drug Deliv Rev. 46:75-87 (2001). 
54. K. Takeuchi. [Gastroduodenal bicarbonate secretion: pharmacological modulation and 
contribution to mucosal protection]. Nippon Yakurigaku Zasshi. 108:281-293 (1996). 
55. G. Flemstrom, L. Knutson, and E. Kivilaakso. Gastroduodenal mucosal secretion of 
bicarbonate and mucus: physiological control and role in protection. Klin Wochenschr. 
64 Suppl 7:107-111 (1986). 
56. B. Abelow. Understanding acid-base, Lippincott Williams & Wilkins 1998. 
57. W.G. Karr, W.O. Abbott, and A.B. Sample. Intubation Studies Of The Human Small 
Intestine. Iv. Chemical Characteristics Of The Intestinal Contents In The Fasting State 
And As Influenced By The Administration Of Acids, Of Alkalies And Of Water. J Clin 
Invest. 14:893-900 (1935). 
58. D.P. McNamara, K.M. Whitney, and S.L. Goss. Use of a physiologic bicarbonate buffer 
system for dissolution characterization of ionizable drugs. Pharm Res. 20:1641-1646 
(2003). 
59. E.M. Persson, A.S. Gustafsson, A.S. Carlsson, R.G. Nilsson, L. Knutson, P. Forsell, G. 
Hanisch, H. Lennernas, and B. Abrahamsson. The effects of food on the dissolution of 
poorly soluble drugs in human and in model small intestinal fluids. Pharm Res. 
22:2141-2151 (2005). 
60. L. Kalantzi, K. Goumas, V. Kalioras, B. Abrahamsson, J.B. Dressman, and C. Reppas. 
Characterization of the human upper gastrointestinal contents under conditions 
simulating bioavailability/bioequivalence studies. Pharm Res. 23:165-176 (2006). 
61. H. Faddaand A. Basit. Dissolution of pH responsive formulations in media resembling 
intestinal fluids: bicarbonate versus phosphate buffers. J DRUG DELIV SCI TEC. 
15:273-279 (2005). 
62. D.P. McNamaraand G.L. Amidon. Reaction plane approach for estimating the effects of 
buffers on the dissolution rate of acidic drugs. J Pharm Sci. 77:511-517 (1988). 
63. J.J. Sheng, D.P. McNamara, and G.L. Amidon. Toward an in vivo dissolution 
methodology: a comparison of phosphate and bicarbonate buffers. Mol Pharm. 6:29-39 
(2009). 
64. K.G. Mooney, M.A. Mintun, K.J. Himmelstein, and V.J. Stella. Dissolution kinetics of 
carboxylic acids II: effect of buffers. J Pharm Sci. 70:22-32 (1981). 
65. A.A. Noyesand W.R. Whitney. THE RATE OF SOLUTION OF SOLID SUBSTANCES 
IN THEIR OWN SOLUTIONS. Journal of the American Chemical Society. 19:930-934 
 96
(1897). 
66. E. BRUNNER. Reaktionsgeschwindigkeit in heterogenen systemen. ZPhysChem. 
47:56-102 (1904). 
67. W.NERNST. Theorie der Reaktions-geschwindigkeit in heterogenen systemen. 
ZPhysChem. 47:52-55 (1904). 
68. W. Weibull. A STATISTICAL DISTRIBUTION FUNCTION OF WIDE 
APPLICABILITY. Journal of Applied Mechanics-Transactions of the Asme. 18:293-297 
(1951). 
69. T.C. Tsu, R.A. Mugele, and F.A. Mcclintock. A Statistical Distribution Function of Wide 
Applicability. Journal of Applied Mechanics-Transactions of the Asme. 19:233-234 
(1952). 
70. M. Bisrat, E.K. Anderberg, M.I. Barnett, and C. Nyström. Physicochemical aspects of 
drug release. XV. Investigation of diffusional transport in dissolution of suspended, 
sparingly soluble drugs. International Journal of Pharmaceutics. 80:191-201 (1992). 
71. D. OLANDER. THE INTERNAL CONSISTENCY OF SIMULTANEOUS HEAT AND 
MASS TRANSFER RELATIONSHIPS. AICHE J. 6:346-347 (1960). 
72. D. OLANDER. SIMULTANEOUS MASS TRANSFER AND EQUILIBRIUM 
CHEMICAL REACTION. AICHE J. 6:233-239 (1960). 
73. K.G. Mooney, M.A. Mintun, K.J. Himmelstein, and V.J. Stella. Dissolution kinetics of 
carboxylic acids I: effect of pH under unbuffered conditions. J Pharm Sci. 70:13-22 
(1981). 
74. D.P. McNamaraand G.L. Amidon. Dissolution of acidic and basic compounds from the 
rotating disk: influence of convective diffusion and reaction. J Pharm Sci. 75:858-868 
(1986). 
75. J.E. Boni, R.S. Brickl, and J. Dressman. Is bicarbonate buffer suitable as a dissolution 
medium? J Pharm Pharmacol. 59:1375-1382 (2007). 
76. E.L. McConnell, H.M. Fadda, and A.W. Basit. Gut instincts: explorations in intestinal 
physiology and drug delivery. Int J Pharm. 364:213-226 (2008). 
77. J.B. Dressman, P. Bass, W.A. Ritschel, D.R. Friend, A. Rubinstein, and E. Ziv. 
Gastrointestinal parameters that influence oral medications. J Pharm Sci. 82:857-872 
(1993). 
78. H.M. Fadda, H.A. Merchant, B.T. Arafat, and A.W. Basit. Physiological bicarbonate 
buffers: Stabilisation and use as dissolution media for modified release systems. Int J 
Pharm (2009). 
79. K. Takeuchi. Bicarbonate secretion in the mucosal defensive mechanism of the 
duodenum. Acid neutralization with HCO3- in the lumen and mucus gel. Yakugaku 
Zasshi. 110:85-104 (1990). 
80. F.J. Gennariand W.J. Weise. Acid-base disturbances in gastrointestinal disease. Clin J 
Am Soc Nephrol. 3:1861-1868 (2008). 
81. M. Repishti, D.L. Hogan, V. Pratha, L. Davydova, M. Donowitz, C.M. Tse, and J.I. 
Isenberg. Human duodenal mucosal brush border Na(+)/H(+) exchangers NHE2 and 
NHE3 alter net bicarbonate movement. Am J Physiol Gastrointest Liver Physiol. 
281:G159-163 (2001). 
82. V.C. Ibekwe, F. Liu, H.M. Fadda, M.K. Khela, D.F. Evans, G.E. Parsons, and A.W. Basit. 
 97
An investigation into the in vivo performance variability of pH responsive polymers for 
ileo-colonic drug delivery using gamma scintigraphy in humans. J Pharm Sci. 
95:2760-2766 (2006). 
83. V.C. Ibekwe, H.M. Fadda, G.E. Parsons, and A.W. Basit. A comparative in vitro 
assessment of the drug release performance of pH-responsive polymers for ileo-colonic 
delivery. Int J Pharm. 308:52-60 (2006). 
84. H. Lennernas, O. Ahrenstedt, R. Hallgren, L. Knutson, M. Ryde, and L.K. Paalzow. 
Regional jejunal perfusion, a new in vivo approach to study oral drug absorption in man. 
Pharm Res. 9:1243-1251 (1992). 
85. L. Knutson, B. Odlind, and R. Hallgren. A new technique for segmental jejunal 
perfusion in man. Am J Gastroenterol. 84:1278-1284 (1989). 
86. M. Perez de la Cruz Moreno, M. Oth, S. Deferme, F. Lammert, J. Tack, J. Dressman, 
and P. Augustijns. Characterization of fasted-state human intestinal fluids collected from 
duodenum and jejunum. J Pharm Pharmacol. 58:1079-1089 (2006). 
87. A.N. Martin. Physical Pharmacy, Lea &Febiger, 1993. 
88. M.J. Welch, J.F. Lifton, and J.A. Seck. Tracer studies with radioactive oxygen-15. 
Exchange between carbon dioxide and water. The Journal of Physical Chemistry. 
73:3351-3356 (1969). 
89. S.J. Rune. Acid-base parameters of duodenal contents in man. Gastroenterology. 
62:533-539 (1972). 
90. J.J. Kolkman, J.A. Otte, and A.B. Groeneveld. Gastrointestinal luminal PCO2 
tonometry: an update on physiology, methodology and clinical applications. Br J 
Anaesth. 84:74-86 (2000). 
91. R.A.L. Judy Hankins, Carolyn Hedrick , Maxine Perdue Infusion therapy in clinical 
practice, Saunders, 2001. 
92. S. Spiegel, M. Phillipper, H. Rossmann, B. Riederer, M. Gregor, and U. Seidler. 
Independence of apical Cl-/HCO3- exchange and anion conductance in duodenal HCO3- 
secretion. Am J Physiol Gastrointest Liver Physiol. 285:G887-897 (2003). 
93. Z. Wang, S. Petrovic, E. Mann, and M. Soleimani. Identification of an apical 
Cl(-)/HCO3(-) exchanger in the small intestine. Am J Physiol Gastrointest Liver Physiol. 
282:G573-579 (2002). 
94. M. Gray, C. O'Reilly, J. Winpenny, and B. Argent. Anion interactions with CFTR and 
consequences for HCO3- transport in secretory epithelia. J Korean Med Sci. 15 
Suppl:S12-15 (2000). 
95. T.W. Knutson, M.A. Koss, D.L. Hogan, J.I. Isenberg, and L. Knutson. Acetazolamide 
inhibits basal and stimulated HCO3- secretion in the human proximal duodenum. 
Gastroenterology. 108:102-107 (1995). 
96. A. Allenand G. Flemstrom. Gastroduodenal mucus bicarbonate barrier: protection 
against acid and pepsin. Am J Physiol Cell Physiol. 288:C1-19 (2005). 
97. G. Flemstrom. Gastroduodenal mucosal secretion of bicarbonate and mucus. Physiologic 
control and stimulation by prostaglandins. Am J Med. 81:18-22 (1986). 
98. G. Flemstrom, G. Jedstedt, and O. Nylander. Effects of some opiates and vasoactive 
intestinal peptide (VIP) on duodenal surface epithelial bicarbonate secretion in the rat. 
Scand J Gastroenterol Suppl. 110:49-53 (1985). 
 98
99. J.J. Holst, J. Fahrenkrug, S. Knuhtsen, S.L. Jensen, S.S. Poulsen, and O.V. Nielsen. 
Vasoactive intestinal polypeptide (VIP) in the pig pancreas: role of VIPergic nerves in 
control of fluid and bicarbonate secretion. Regul Pept. 8:245-259 (1984). 
100. D.L. Hogan, M.A. Ainsworth, and J.I. Isenberg. Review article: gastroduodenal 
bicarbonate secretion. Aliment Pharmacol Ther. 8:475-488 (1994). 
101. Y. Akiba, M. Mizumori, P.H. Guth, E. Engel, and J.D. Kaunitz. Duodenal brush border 
intestinal alkaline phosphatase activity affects bicarbonate secretion in rats. Am J 
Physiol Gastrointest Liver Physiol. 293:G1223-1233 (2007). 
102. M.A. Ainsworthand J. Kjeldsen. [Defense mechanisms of the gastroduodenal mucosa: 
the role of mucus and bicarbonate in the development of peptic ulcer]. Ugeskr Laeger. 
151:2708-2713 (1989). 
103. D.L. Hogan, R.C. Rapier, A. Dreilinger, M.A. Koss, P.M. Basuk, W.M. Weinstein, L.M. 
Nyberg, and J.I. Isenberg. Duodenal bicarbonate secretion: eradication of Helicobacter 
pylori and duodenal structure and function in humans. Gastroenterology. 110:705-716 
(1996). 
104. G. Flemstrom, A. Bergman, and S. Briden. Stimulation of mucosal bicarbonate secretion 
in rat duodenum in vivo by BW755C. Acta Physiol Scand. 121:39-43 (1984). 
105. M. Mizumori, J. Meyerowitz, T. Takeuchi, S. Lim, P. Lee, C.T. Supuran, P.H. Guth, E. 
Engel, J.D. Kaunitz, and Y. Akiba. Epithelial carbonic anhydrases facilitate PCO2 and 
pH regulation in rat duodenal mucosa. J Physiol. 573:827-842 (2006). 
106. E. Jantratid, N. Janssen, C. Reppas, and J.B. Dressman. Dissolution media simulating 
conditions in the proximal human gastrointestinal tract: an update. Pharm Res. 
25:1663-1676 (2008). 
107. V.G. Levich. Physicochemical Hydrodynamics, Prentice-Hall, Englewood Cliffs, NJ, 
1962. 
108. P.L. Oravecand E.L. Parrott. Chemical reaction, diffusion, and ionization model for 
dissolution of oxygen acids and carbon acids. J Pharm Sci. 74:175-179 (1985). 
109. M. Littand G. Serad. Chemical reactions on a rotating disk. Chemical Engineering 
Science. 19:867-884 (1964). 
110. W.I. Higuchi, E.L. Parrott, D.E. Wurster, and T. Higuchi. Investigation of drug release 
from solids. II. Theoretical and experimental study of influences of bases and buffers on 
rates of dissolution of acidic solids. J Am Pharm Assoc Am Pharm Assoc (Baltim). 
47:376-383 (1958). 
111. H.S. Harnedand R. Davis. The Ionization Constant of Carbonic Acid in Water and the 
Solubility of Carbon Dioxide in Water and Aqueous Salt Solutions from 0 to 50C. 
Journal of the American Chemical Society. 65:2030-2037 (2002). 
112. B.H. Gibbonsand J.T. Edsall. Rate of Hydration of Carbon Dioxide and Dehydration of 
Carbonic Acid at 25 Degrees. J Biol Chem. 238:3502-3507 (1963). 
113. G. Malnicand G. Giebisch. Symposium on acid-base homeostasis. Mechanism of renal 
hydrogenion secretion. Kidney Int. 1:280-296 (1972). 
114. T.W.P. Burton David Rose. Clinical physiology of acid-base and electrolyte disorders, 
McGraw-Hill Professional, 2001. 
115. P.A. Cox. Instant notes inorganic chemistry, BIOS Scientific Publishers, London and 
New York, 2004. 
 99
116. USP30-NF25, United States Pharmacopoeal Convention (USPC) Inc, Rockville, MD, 
2007. 
117. European Pharmacopoeia, Strasbourg France, 2001. 
118. The International Pharmacopoeia, World Health Organization, Geneva, 2003. 
119. A. Avdeef, C.M. Berger, and C. Brownell. pH-Metric Solubility. 2: Correlation Between 
the Acid-Base Titration and the Saturation Shake-Flask Solubility-pH Methods. 
Pharmaceutical Research. 17:85-89 (2000). 
120. W. Haydukand H. Laudie. Prediction of diffusion coefficients for nonelectrolytes in 
dilute aqueous solutions. AICHE J. 20:611-615 (1974). 
121. E.L.Cussler. Diffusion : Mass Transfer in Fluid Systems, Cambridge University Press, 
Cambridge, 1997. 
122. J.R. Vinogradand J.W. McBain. Diffusion of Electrolytes and of the Ions in their 
Mixtures. Journal of the American Chemical Society. 63:2008-2015 (1941). 
123. S. Breton. The cellular physiology of carbonic anhydrases. Jop. 2:159-164 (2001). 
124. R.E. Fleming, S. Parkkila, A.K. Parkkila, H. Rajaniemi, A. Waheed, and W.S. Sly. 
Carbonic anhydrase IV expression in rat and human gastrointestinal tract regional, 
cellular, and subcellular localization. J Clin Invest. 96:2907-2913 (1995). 
125. S.P.a.J. Z΅vada. Carbonic anhydrase IX (CA IX) as a potential target for cancer therapy. 
Cancer Therapy. 2:245-262 (2004). 
126. J.M. Purkersonand G.J. Schwartz. Expression of membrane-associated carbonic 
anhydrase isoforms IV, IX, XII, and XIV in the rabbit: induction of CA IV and IX 
during maturation. Am J Physiol Regul Integr Comp Physiol. 288:R1256-1263 (2005). 
127. W.T.C. Donald E. Leyden. Chemically modified surfaces in scineces and industry: 
proceddings of the chemically modified surfaces symposium, Gordon and Breach 
Science Publisher, New York, NY, 1988. 
128. G. Lonnerholm, O. Selking, and P.J. Wistrand. Amount and distribution of carbonic 
anhydrases CA I and CA II in the gastrointestinal tract. Gastroenterology. 88:1151-1161 
(1985). 
129. M.J. Carterand D.S. Parsons. Carbonic anhydrase activity of mucosa of small intestine 
and colon. Nature. 219:176-177 (1968). 
130. R.T. Fernley, R.D. Wright, and J.P. Coghlan. Radioimmunoassay of carbonic anhydrase 
VI in saliva and sheep tissues. Biochem J. 274 ( Pt 2):313-316 (1991). 
131. S. Parkkila, A.K. Parkkila, J. Lehtola, A. Reinila, H.J. Sodervik, M. Rannisto, and H. 
Rajaniemi. Salivary carbonic anhydrase protects gastroesophageal mucosa from acid 
injury. Dig Dis Sci. 42:1013-1019 (1997). 
132. S. Parkkila, A.K. Parkkila, T. Vierjoki, T. Stahlberg, and H. Rajaniemi. Competitive 
time-resolved immunofluorometric assay for quantifying carbonic anhydrase VI in 
saliva. Clin Chem. 39:2154-2157 (1993). 
133. S. Parkkilaand A.K. Parkkila. Carbonic anhydrase in the alimentary tract. Roles of the 
different isozymes and salivary factors in the maintenance of optimal conditions in the 
gastrointestinal canal. Scand J Gastroenterol. 31:305-317 (1996). 
134. S.J. Runeand F.W. Henriksen. Carbon dioxide tensions in the proximal part of the 
canine gastrointestinal tract. Gastroenterology. 56:758-762 (1969). 
135. J.P. Fettand J.R. Coleman. Regulation of Periplasmic Carbonic Anhydrase Expression in 
 100
Chlamydomonas reinhardtii by Acetate and pH. Plant Physiol. 106:103-108 (1994). 
136. S. Wang, Y. Liu, Y. Zou, and D. Li. Modulation and adaptation of carbonic anhydrase 
activity in Microcystis spp. under different environmental factors. Acta Ecologica Sinica. 
26:2443-2448 (2006). 
137. E. Galia, E. Nicolaides, D. Horter, R. Lobenberg, C. Reppas, and J.B. Dressman. 
Evaluation of various dissolution media for predicting in vivo performance of class I and 
II drugs. Pharm Res. 15:698-705 (1998). 
138. J.B. Dressman, G.L. Amidon, C. Reppas, and V.P. Shah. Dissolution testing as a 
prognostic tool for oral drug absorption: immediate release dosage forms. Pharm Res. 
15:11-22 (1998). 
 
 
